Form: 10-Q

Quarterly report pursuant to Section 13 or 15(d)

October 28, 2021

false2021Q30001659166December 310.400.400.010956810000016591662021-01-012021-10-01xbrli:shares00016591662021-10-25iso4217:USD00016591662021-10-0100016591662020-12-31iso4217:USDxbrli:sharesxbrli:pure00016591662020-01-012020-12-310001659166us-gaap:ProductMember2021-07-032021-10-010001659166us-gaap:ProductMember2020-06-272020-09-250001659166us-gaap:ProductMember2021-01-012021-10-010001659166us-gaap:ProductMember2020-01-012020-09-250001659166us-gaap:ServiceMember2021-07-032021-10-010001659166us-gaap:ServiceMember2020-06-272020-09-250001659166us-gaap:ServiceMember2021-01-012021-10-010001659166us-gaap:ServiceMember2020-01-012020-09-2500016591662021-07-032021-10-0100016591662020-06-272020-09-2500016591662020-01-012020-09-250001659166us-gaap:CommonStockMember2020-12-310001659166us-gaap:PreferredStockMember2020-12-310001659166us-gaap:AdditionalPaidInCapitalMember2020-12-310001659166us-gaap:RetainedEarningsMember2020-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001659166us-gaap:NoncontrollingInterestMember2020-12-310001659166us-gaap:RetainedEarningsMember2021-01-012021-04-020001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-04-020001659166us-gaap:CommonStockMember2021-01-012021-04-020001659166us-gaap:AdditionalPaidInCapitalMember2021-01-012021-04-020001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2021-04-020001659166us-gaap:NoncontrollingInterestMember2021-01-012021-04-020001659166us-gaap:CommonStockMember2021-04-020001659166us-gaap:PreferredStockMember2021-04-020001659166us-gaap:AdditionalPaidInCapitalMember2021-04-020001659166us-gaap:RetainedEarningsMember2021-04-020001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-020001659166us-gaap:NoncontrollingInterestMember2021-04-020001659166us-gaap:RetainedEarningsMember2021-04-032021-07-020001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-032021-07-020001659166us-gaap:CommonStockMember2021-04-032021-07-020001659166us-gaap:AdditionalPaidInCapitalMember2021-04-032021-07-020001659166us-gaap:PreferredStockMember2021-04-032021-07-020001659166us-gaap:NoncontrollingInterestMember2021-04-032021-07-020001659166us-gaap:CommonStockMember2021-07-020001659166us-gaap:PreferredStockMember2021-07-020001659166us-gaap:AdditionalPaidInCapitalMember2021-07-020001659166us-gaap:RetainedEarningsMember2021-07-020001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-020001659166us-gaap:NoncontrollingInterestMember2021-07-020001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-032021-10-010001659166us-gaap:RetainedEarningsMember2021-07-032021-10-010001659166us-gaap:CommonStockMember2021-07-032021-10-010001659166us-gaap:AdditionalPaidInCapitalMember2021-07-032021-10-010001659166us-gaap:NoncontrollingInterestMember2021-07-032021-10-010001659166us-gaap:CommonStockMember2021-10-010001659166us-gaap:PreferredStockMember2021-10-010001659166us-gaap:AdditionalPaidInCapitalMember2021-10-010001659166us-gaap:RetainedEarningsMember2021-10-010001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-10-010001659166us-gaap:NoncontrollingInterestMember2021-10-010001659166us-gaap:CommonStockMember2019-12-310001659166us-gaap:PreferredStockMember2019-12-310001659166us-gaap:AdditionalPaidInCapitalMember2019-12-310001659166us-gaap:RetainedEarningsMember2019-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001659166us-gaap:NoncontrollingInterestMember2019-12-310001659166us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:CommonStockMember2019-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:PreferredStockMember2019-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AdditionalPaidInCapitalMember2019-12-310001659166us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2019-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:NoncontrollingInterestMember2019-12-310001659166us-gaap:RetainedEarningsMember2020-01-012020-03-270001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-270001659166us-gaap:CommonStockMember2020-01-012020-03-270001659166us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-270001659166us-gaap:NoncontrollingInterestMember2020-01-012020-03-270001659166us-gaap:CommonStockMember2020-03-270001659166us-gaap:PreferredStockMember2020-03-270001659166us-gaap:AdditionalPaidInCapitalMember2020-03-270001659166us-gaap:RetainedEarningsMember2020-03-270001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-270001659166us-gaap:NoncontrollingInterestMember2020-03-270001659166us-gaap:RetainedEarningsMember2020-03-282020-06-260001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-282020-06-260001659166us-gaap:CommonStockMember2020-03-282020-06-260001659166us-gaap:AdditionalPaidInCapitalMember2020-03-282020-06-260001659166us-gaap:NoncontrollingInterestMember2020-03-282020-06-260001659166us-gaap:CommonStockMember2020-06-260001659166us-gaap:PreferredStockMember2020-06-260001659166us-gaap:AdditionalPaidInCapitalMember2020-06-260001659166us-gaap:RetainedEarningsMember2020-06-260001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-260001659166us-gaap:NoncontrollingInterestMember2020-06-260001659166us-gaap:RetainedEarningsMember2020-06-272020-09-250001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-272020-09-250001659166us-gaap:CommonStockMember2020-06-272020-09-250001659166us-gaap:AdditionalPaidInCapitalMember2020-06-272020-09-250001659166us-gaap:NoncontrollingInterestMember2020-06-272020-09-250001659166us-gaap:CommonStockMember2020-09-250001659166us-gaap:PreferredStockMember2020-09-250001659166us-gaap:AdditionalPaidInCapitalMember2020-09-250001659166us-gaap:RetainedEarningsMember2020-09-250001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-250001659166us-gaap:NoncontrollingInterestMember2020-09-2500016591662019-12-3100016591662020-09-250001659166ftv:VontierMember2020-10-090001659166ftv:VontierMember2020-10-092020-10-090001659166ftv:VontierMember2021-01-190001659166ftv:VontierMember2021-01-19iso4217:JPY0001659166ftv:YenTermLoanMember2020-09-250001659166us-gaap:AccumulatedTranslationAdjustmentMember2021-07-020001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-020001659166us-gaap:AccumulatedTranslationAdjustmentMember2021-07-032021-10-010001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-032021-10-010001659166us-gaap:AccumulatedTranslationAdjustmentMember2021-10-010001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-10-010001659166us-gaap:AccumulatedTranslationAdjustmentMember2020-06-260001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-260001659166us-gaap:AccumulatedTranslationAdjustmentMember2020-06-272020-09-250001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-272020-09-250001659166us-gaap:AccumulatedTranslationAdjustmentMember2020-09-250001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-250001659166us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-10-010001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-10-010001659166us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-250001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-250001659166ftv:AcquisitionsASPMember2019-04-012019-04-01ftv:country0001659166ftv:AcquisitionsASPMember2021-01-012021-10-010001659166ftv:AcquisitionsASPMember2021-10-010001659166ftv:ServiceChannelMember2021-08-242021-08-240001659166ftv:ServiceChannelMember2021-10-010001659166ftv:ServiceChannelMember2020-01-012020-12-310001659166ftv:ServiceChannelMember2021-01-012021-10-010001659166ftv:ServiceChannelMember2021-07-032021-10-010001659166ftv:TelematicsReportingUnitMember2020-01-012020-03-270001659166ftv:VontierMemberus-gaap:SegmentDiscontinuedOperationsMember2021-07-032021-10-010001659166ftv:VontierMemberus-gaap:SegmentDiscontinuedOperationsMember2020-06-272020-09-250001659166ftv:VontierMemberus-gaap:SegmentDiscontinuedOperationsMember2021-01-012021-10-010001659166ftv:VontierMemberus-gaap:SegmentDiscontinuedOperationsMember2020-01-012020-09-250001659166ftv:VontierMemberus-gaap:SegmentDiscontinuedOperationsMember2021-10-010001659166ftv:VontierMemberus-gaap:SegmentDiscontinuedOperationsMember2020-12-310001659166ftv:IntelligentOperatingSolutionsMember2020-12-310001659166ftv:PrecisionTechnologiesMember2020-12-310001659166ftv:AdvancedHealthcareSolutionsMember2020-12-310001659166ftv:IntelligentOperatingSolutionsMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMember2021-10-010001659166ftv:PrecisionTechnologiesMember2021-10-010001659166ftv:AdvancedHealthcareSolutionsMember2021-10-010001659166ftv:PatentsAndTechnologyBasedIntangibleAssetsMember2021-10-010001659166ftv:PatentsAndTechnologyBasedIntangibleAssetsMember2020-12-310001659166ftv:CustomerRelationshipsAndOtherIntangiblesMember2021-10-010001659166ftv:CustomerRelationshipsAndOtherIntangiblesMember2020-12-310001659166us-gaap:TrademarksAndTradeNamesMember2021-10-010001659166us-gaap:TrademarksAndTradeNamesMember2020-12-310001659166us-gaap:TrademarksAndTradeNamesMember2021-10-010001659166us-gaap:TrademarksAndTradeNamesMember2020-12-310001659166ftv:CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember2021-07-032021-10-010001659166ftv:CustomerRelationshipsDevelopedTechnologyAndTradeNamesMember2021-01-012021-10-010001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-10-010001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-10-010001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-10-010001659166us-gaap:FairValueMeasurementsRecurringMember2021-10-010001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001659166us-gaap:FairValueMeasurementsRecurringMember2020-12-310001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDueMarch2021Member2021-01-190001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDueMarch2021Member2021-01-192021-01-190001659166ftv:DelayedDrawTermLoanDueMay2021Memberus-gaap:LineOfCreditMember2021-01-190001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDueMarch2021AndDelayedDrawTermLoanDueMay2021Member2021-01-012021-10-010001659166us-gaap:FairValueInputsLevel1Member2021-10-010001659166us-gaap:FairValueInputsLevel1Member2020-12-310001659166us-gaap:SeniorNotesMemberftv:SeniorUnsecuredNotesdue2026Member2021-10-010001659166us-gaap:SeniorNotesMemberftv:SeniorUnsecuredNotesdue2026Member2020-12-310001659166us-gaap:SeniorNotesMemberftv:SeniorUnsecuredNotesdue2046Member2021-10-010001659166us-gaap:SeniorNotesMemberftv:SeniorUnsecuredNotesdue2046Member2020-12-310001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2021-10-010001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2020-12-310001659166ftv:DelayedDrawTermLoanDueMay2021Memberus-gaap:LineOfCreditMember2021-10-010001659166ftv:DelayedDrawTermLoanDueMay2021Memberus-gaap:LineOfCreditMember2020-12-310001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDueMarch2021Member2021-10-010001659166us-gaap:LineOfCreditMemberftv:DelayedDrawTermLoanDueMarch2021Member2020-12-310001659166ftv:DelayedDrawTermLoanDueMay2021Memberus-gaap:LineOfCreditMember2021-01-212021-01-210001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2019-02-222019-02-220001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2019-02-220001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesdue2022OverAllotmentOptionMember2019-02-220001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2021-02-090001659166us-gaap:ConvertibleDebtMember2021-01-012021-10-010001659166us-gaap:AdditionalPaidInCapitalMember2021-02-092021-02-090001659166us-gaap:ConvertibleDebtMember2021-07-032021-10-010001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2021-07-032021-10-010001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2021-01-012021-10-010001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2020-06-272020-09-250001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2020-01-012020-09-250001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2020-09-250001659166us-gaap:CommercialPaperMemberftv:USDollarDenominatedCommercialPaperMember2021-10-010001659166us-gaap:CommercialPaperMemberftv:USDollarDenominatedCommercialPaperMember2021-01-012021-10-010001659166us-gaap:RevolvingCreditFacilityMember2021-01-012021-10-010001659166us-gaap:RevolvingCreditFacilityMember2021-10-010001659166us-gaap:ConvertibleDebtMemberftv:SeniorConvertibleNotesDue2022Member2020-10-092020-10-090001659166srt:MaximumMemberftv:DeferredSalesCommissionsMember2021-10-010001659166srt:MinimumMember2021-10-010001659166srt:MaximumMember2021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-10-0100016591662021-10-02ftv:PeriodOneMember2021-10-0100016591662021-10-02ftv:PeriodTwoMember2021-10-0100016591662021-10-02ftv:PeriodThreeMember2021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166us-gaap:ServiceMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166country:US2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2021-07-032021-10-010001659166country:CN2021-07-032021-10-010001659166country:CNftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166country:CNftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166country:CNftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:CountriesExcludingUnitedStatesandChinaMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2021-07-032021-10-010001659166ftv:MedicalMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2021-07-032021-10-010001659166ftv:IndustrialManufacturingMember2021-07-032021-10-010001659166ftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:IndustrialManufacturingMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:IndustrialManufacturingMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:UtilitiesPowerMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2021-07-032021-10-010001659166us-gaap:GovernmentMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:CommunicationElectronicsAndSemiconductorMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2021-07-032021-10-010001659166ftv:AerospaceAndDefenseMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2021-07-032021-10-010001659166us-gaap:OilAndGasMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:RetailAndConsumerMember2021-07-032021-10-010001659166ftv:RetailAndConsumerMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:RetailAndConsumerMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:RetailAndConsumerMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:OtherDirectEndMarketsMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:OtherDirectEndMarketsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:OtherDirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:DirectEndMarketsMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:PrecisionTechnologiesMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:DirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:OtherDistributorsMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:OtherDistributorsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:OtherDistributorsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-07-032021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166us-gaap:ServiceMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166country:US2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMembercountry:US2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2020-06-272020-09-250001659166country:CN2020-06-272020-09-250001659166country:CNftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166country:CNftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166country:CNftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:CountriesExcludingUnitedStatesandChinaMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-06-272020-09-250001659166ftv:MedicalMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2020-06-272020-09-250001659166ftv:IndustrialManufacturingMember2020-06-272020-09-250001659166ftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:IndustrialManufacturingMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:IndustrialManufacturingMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:UtilitiesPowerMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2020-06-272020-09-250001659166us-gaap:GovernmentMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:CommunicationElectronicsAndSemiconductorMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2020-06-272020-09-250001659166ftv:AerospaceAndDefenseMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2020-06-272020-09-250001659166us-gaap:OilAndGasMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:RetailAndConsumerMember2020-06-272020-09-250001659166ftv:RetailAndConsumerMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:RetailAndConsumerMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:RetailAndConsumerMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:OtherDirectEndMarketsMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:OtherDirectEndMarketsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:OtherDirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:DirectEndMarketsMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:PrecisionTechnologiesMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:DirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:OtherDistributorsMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:OtherDistributorsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:OtherDistributorsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-06-272020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166us-gaap:ServiceMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166country:US2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2021-01-012021-10-010001659166country:CN2021-01-012021-10-010001659166country:CNftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166country:CNftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166country:CNftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:CountriesExcludingUnitedStatesandChinaMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2021-01-012021-10-010001659166ftv:MedicalMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2021-01-012021-10-010001659166ftv:IndustrialManufacturingMember2021-01-012021-10-010001659166ftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:IndustrialManufacturingMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:IndustrialManufacturingMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:UtilitiesPowerMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2021-01-012021-10-010001659166us-gaap:GovernmentMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:CommunicationElectronicsAndSemiconductorMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2021-01-012021-10-010001659166ftv:AerospaceAndDefenseMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2021-01-012021-10-010001659166us-gaap:OilAndGasMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:RetailAndConsumerMember2021-01-012021-10-010001659166ftv:RetailAndConsumerMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:RetailAndConsumerMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:RetailAndConsumerMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:OtherDirectEndMarketsMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:OtherDirectEndMarketsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:OtherDirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:DirectEndMarketsMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:PrecisionTechnologiesMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:DirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:OtherDistributorsMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:OtherDistributorsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:OtherDistributorsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-10-010001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166us-gaap:ServiceMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166country:US2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-250001659166country:CN2020-01-012020-09-250001659166country:CNftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166country:CNftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166country:CNftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMember2020-01-012020-09-250001659166ftv:MedicalMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:MedicalMember2020-01-012020-09-250001659166ftv:IndustrialManufacturingMember2020-01-012020-09-250001659166ftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:IndustrialManufacturingMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:IndustrialManufacturingMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:UtilitiesPowerMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMember2020-01-012020-09-250001659166us-gaap:GovernmentMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:GovernmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:CommunicationElectronicsAndSemiconductorMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:CommunicationElectronicsAndSemiconductorMember2020-01-012020-09-250001659166ftv:AerospaceAndDefenseMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMemberftv:AerospaceAndDefenseMember2020-01-012020-09-250001659166us-gaap:OilAndGasMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:RetailAndConsumerMember2020-01-012020-09-250001659166ftv:RetailAndConsumerMemberftv:IntelligentOperatingSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:RetailAndConsumerMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:RetailAndConsumerMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:OtherDirectEndMarketsMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:OtherDirectEndMarketsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:OtherDirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:DirectEndMarketsMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:PrecisionTechnologiesMemberftv:DirectEndMarketsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:DirectEndMarketsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:OtherDistributorsMember2020-01-012020-09-250001659166ftv:IntelligentOperatingSolutionsMemberftv:OtherDistributorsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:OtherDistributorsMemberftv:PrecisionTechnologiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166ftv:OtherDistributorsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OperatingSegmentsMember2020-01-012020-09-250001659166country:US2021-07-032021-10-010001659166country:US2020-06-272020-09-250001659166country:US2021-01-012021-10-010001659166country:US2020-01-012020-09-250001659166us-gaap:ForeignPlanMember2021-07-032021-10-010001659166us-gaap:ForeignPlanMember2020-06-272020-09-250001659166us-gaap:ForeignPlanMember2021-01-012021-10-010001659166us-gaap:ForeignPlanMember2020-01-012020-09-250001659166us-gaap:ForeignPlanMember2021-10-010001659166country:US2021-10-010001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2021-07-032021-10-010001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2020-06-272020-09-250001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2021-01-012021-10-010001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2020-01-012020-09-250001659166us-gaap:EmployeeStockOptionMember2021-07-032021-10-010001659166us-gaap:EmployeeStockOptionMember2020-06-272020-09-250001659166us-gaap:EmployeeStockOptionMember2021-01-012021-10-010001659166us-gaap:EmployeeStockOptionMember2020-01-012020-09-250001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2021-10-010001659166us-gaap:EmployeeStockOptionMember2021-10-010001659166us-gaap:EmployeeStockOptionMember2021-07-032021-10-010001659166us-gaap:EmployeeStockOptionMember2020-06-272020-09-250001659166us-gaap:EmployeeStockOptionMember2021-01-012021-10-010001659166us-gaap:EmployeeStockOptionMember2020-01-012020-09-2500016591662021-07-012021-07-0100016591662021-07-010001659166us-gaap:CommonStockMember2021-07-012021-07-0100016591662021-01-012021-04-0200016591662021-04-032021-07-0200016591662020-01-012020-03-2700016591662020-03-282020-06-26ftv:segment0001659166us-gaap:CorporateNonSegmentMember2021-07-032021-10-010001659166us-gaap:CorporateNonSegmentMember2020-06-272020-09-250001659166us-gaap:CorporateNonSegmentMember2021-01-012021-10-010001659166us-gaap:CorporateNonSegmentMember2020-01-012020-09-25


 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________
FORM 10-Q
 ________________________________________________
(Mark One)  
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: October 1, 2021
Or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to            
Commission file number 1-37654
 ________________________________________________
Fortive Corporation
(Exact name of registrant as specified in its charter)
________________________________________________ 
 
Delaware   47-5654583
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. employer
identification number)
6920 Seaway Blvd
Everett, WA 98203
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (425) 446-5000

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol Name of each exchange on which registered
Common stock, par value $0.01 per share FTV New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.









Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes  No 
The number of shares of common stock outstanding at October 25, 2021 was 358,577,652.




FORTIVE CORPORATION
INDEX
FORM 10-Q
 
PART I - FINANCIAL INFORMATION Page
Item 1.
Item 2.
Item 3.
Item 4.
PART II - OTHER INFORMATION
Item 1A.
Item 2.
Item 6.



Table of Contents
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS



Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ in millions, except per share amounts)
  As of
  October 1, 2021 December 31, 2020
  (unaudited)  
ASSETS
Current assets:
Cash and equivalents $ 838.4  $ 1,824.8 
Accounts receivable, net 830.4  810.3 
Inventories:
Finished goods 231.1  227.9 
Work in process 87.9  75.2 
Raw materials 187.8  152.4 
Inventories 506.8  455.5 
Prepaid expenses and other current assets 249.7  206.7 
Investment in Vontier Corporation   1,119.2 
Current assets, discontinued operations   30.4 
Total current assets 2,425.3  4,446.9 
Property, plant and equipment, net of accumulated depreciation of $701.1 and $674.5 at October 1, 2021 and December 31, 2020, respectively
395.0  422.0 
Operating lease right-of-use assets 180.3  188.7 
Other assets 361.9  344.1 
Goodwill 8,221.5  7,359.2 
Other intangible assets, net 3,392.1  3,290.6 
Total assets $ 14,976.1  $ 16,051.5 
LIABILITIES AND EQUITY
Current liabilities:
Commercial paper $ 215.0  $  
Current portion of long-term debt 1,143.2  1,399.8 
Trade accounts payable 494.9  480.8 
Current operating lease liabilities 45.4  47.0 
Accrued expenses and other current liabilities 969.2  899.9 
Current liabilities, discontinued operations 1.2  33.3 
Total current liabilities 2,868.9  2,860.8 
Operating lease liabilities 144.3  154.3 
Other long-term liabilities 1,198.0  1,233.4 
Long-term debt 1,442.1  2,830.3 
Commitments and Contingencies
Equity:
Preferred stock: $0.01 par value, 15.0 million shares authorized at October 1, 2021 and December 31, 2020; 5.0% Mandatory convertible preferred stock, series A, 0.0 million and 1.4 million shares designated, issued, and outstanding at October 1, 2021 and December 31, 2020, respectively
   
Common stock: $0.01 par value, 2.0 billion shares authorized; 359.9 and 339.0 million issued; 358.6 and 337.9 million outstanding at October 1, 2021 and December 31, 2020, respectively
3.6  3.4 
Additional paid-in capital 3,624.3  3,554.5 
Retained earnings 5,882.2  5,547.4 
Accumulated other comprehensive loss (192.1) (141.1)
Total Fortive stockholders’ equity 9,318.0  8,964.2 
Noncontrolling interests 4.8  8.5 
Total stockholders’ equity 9,322.8  8,972.7 
Total liabilities and equity $ 14,976.1  $ 16,051.5 
See the accompanying Notes to Consolidated Condensed Financial Statements.
4

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited) 
  Three Months Ended Nine Months Ended
  October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales of products and software $ 1,105.6  $ 988.1  $ 3,318.8  $ 2,820.6 
Sales of services 193.9  171.7  559.6  488.9 
Total sales 1,299.5  1,159.8  3,878.4  3,309.5 
Cost of product and software sales (448.3) (409.6) (1,356.6) (1,185.8)
Cost of service sales (107.0) (98.6) (310.2) (277.3)
Total cost of sales (555.3) (508.2) (1,666.8) (1,463.1)
Gross profit 744.2  651.6  2,211.6  1,846.4 
Operating costs:
Selling, general and administrative expenses (455.6) (434.8) (1,340.1) (1,253.4)
Research and development expenses (87.8) (79.2) (261.8) (237.4)
Operating profit 200.8  137.6  609.7  355.6 
Non-operating income (expense), net:
Interest expense, net (25.1) (36.9) (78.0) (111.7)
Loss on extinguishment of debt     (104.9)  
Gain on investment in Vontier Corporation     57.0   
Gain on litigation dismissal     26.0   
Other non-operating expense, net (1.6) (1.4) (9.5) (0.3)
Earnings from continuing operations before income taxes 174.1  99.3  500.3  243.6 
Income taxes (23.0) (13.3) (55.5) (43.0)
Net earnings from continuing operations 151.1  86.0  444.8  200.6 
Earnings (loss) from discontinued operations, net of income taxes (0.3) 139.8  (2.9) 197.1 
Net earnings 150.8  225.8  441.9  397.7 
Mandatory convertible preferred dividends   (17.3) (34.5) (51.8)
Net earnings attributable to common stockholders $ 150.8  $ 208.5  $ 407.4  $ 345.9 
Net earnings per common share from continuing operations:
Basic $ 0.42  $ 0.20  $ 1.19  $ 0.44 
Diluted $ 0.42  $ 0.20  $ 1.18  $ 0.44 
Net earnings (loss) per share from discontinued operations:
Basic $   $ 0.41  $ (0.01) $ 0.58 
Diluted $   $ 0.41  $ (0.01) $ 0.58 
Net earnings per share:
Basic $ 0.42  $ 0.62  $ 1.18  $ 1.03 
Diluted $ 0.42  $ 0.61  $ 1.17  $ 1.02 
Average common stock and common equivalent shares outstanding:
Basic 358.9  337.6  345.6  337.3 
Diluted 362.2  340.8  348.8  340.2 
The sum of net earnings per share amounts may not add due to rounding.
See the accompanying Notes to Consolidated Condensed Financial Statements.
5

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
($ in millions)
(unaudited)
 
  Three Months Ended Nine Months Ended
October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Net earnings $ 150.8  $ 225.8  $ 441.9  $ 397.7 
Other comprehensive income, net of income taxes:
Foreign currency translation adjustments (35.7) 63.9  (53.8) (36.4)
Pension adjustments 0.9  1.0  2.8  1.0 
Total other comprehensive income (loss), net of income taxes (34.8) 64.9  (51.0) (35.4)
Comprehensive income $ 116.0  $ 290.7  $ 390.9  $ 362.3 
See the accompanying Notes to Consolidated Condensed Financial Statements.

6

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN EQUITY
($ and shares in millions)
(unaudited)
 
Common Stock Preferred Stock Additional Paid-In Capital Retained Earnings Accumulated
Other
Comprehensive
Income (Loss)
Noncontrolling
Interests
Shares Amount Shares Amount
Balance, December 31, 2020 339.0  $ 3.4  1.4  $   $ 3,554.5  $ 5,547.4  $ (141.1) $ 8.5 
Net earnings for the period —  —  —  —  —  110.2 
Dividends to common shareholders —  —  —  —  —  (23.7) —  — 
Mandatory convertible preferred stock cumulative dividends —  —  —  —  —  (17.3) —  — 
Other comprehensive income (loss) —  —  —  —  —  —  (33.7) — 
Common stock-based award activity (0.5) —  —  —  (2.3) —  —  — 
Early extinguishment of 0.875% senior convertible notes due 2022
—  —  —  —  11.6  —  —  — 
Change in noncontrolling interests —  —  —  —  —  —  —  (0.8)
Balance, April 2, 2021 338.5  $ 3.4  1.4  $   $ 3,563.8  $ 5,616.6  $ (174.8) $ 7.7 
Net earnings for the period —  —  —  —  —  180.9 
Dividends to common shareholders —  —  —  —  —  (23.7) —  — 
Mandatory convertible preferred stock cumulative dividends —  —  —  —  —  (17.2) —  — 
Other comprehensive income —  —  —  —  —  —  17.5  — 
Common stock-based award activity 0.5  —  —  —  35.3  —  —  — 
Conversion of Mandatory convertible preferred stock to common stock 19.4  0.2  (1.4) —  —  —  —  — 
Changes in noncontrolling interests —  —  —  —  3.0  —  —  (3.0)
Balance, July 2, 2021 358.4  $ 3.6    $   $ 3,602.1  $ 5,756.6  $ (157.3) $ 4.7 
Net earnings for the period —  —  —  —  —  150.8 
Dividends to common shareholders —  —  —  —  —  (25.2) —  — 
Other comprehensive income (loss) —  —  —  —  —  —  (34.8) — 
Common stock-based award activity 0.2  —  —  —  26.0  —  —  — 
Changes in noncontrolling interests —  —  —  —  (3.8) —  —  0.1 
Balance, October 1, 2021 358.6  $ 3.6    $   $ 3,624.3  $ 5,882.2  $ (192.1) $ 4.8 


See the accompanying Notes to Consolidated Condensed Financial Statements.
7

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN EQUITY
($ and shares in millions)
(unaudited)
Common Stock Preferred Stock Additional Paid-In Capital Retained Earnings Accumulated
Other
Comprehensive
Income (Loss)
Noncontrolling
Interests
Shares Amount Shares Amount
Balance, December 31, 2019 336.0  $ 3.4  1.4  $   $ 3,311.1  $ 4,128.8  $ (56.3) $ 13.2 
Adoption of accounting standard —  —  —  —  —  (31.3) —  — 
Balance, January 1, 2020 336.0  $ 3.4  1.4  $   $ 3,311.1  $ 4,097.5  $ (56.3) $ 13.2 
Net earnings for the period —  —  —  —  —  41.9  —  — 
Dividends to common shareholders —  —  —  —  —  (23.5) —  — 
Mandatory convertible preferred stock cumulative dividends —  —  —  —  —  (17.3) —  — 
Other comprehensive income (loss) —  —  —  —  —  —  (137.3) — 
Common stock-based award activity 0.8  —  —  —  22.6  —  —  — 
Change in noncontrolling interests —  —  —  —  —  —  —  (2.0)
Balance, March 27, 2020 336.8  $ 3.4  1.4  $   $ 3,333.7  $ 4,098.6  $ (193.6) $ 11.2 
Net earnings for the period —  —  —  —  —  130.0  —  — 
Dividends to common shareholders —  —  —  —  —  (23.6) —  — 
Mandatory convertible preferred stock cumulative dividends —  —  —  —  —  (17.2) —  — 
Other comprehensive income —  —  —  —  —  —  37.0  — 
Common stock-based award activity 0.2  —  —  —  27.0  —  —  — 
Change in noncontrolling interests —  —  —  —  —  —  —  0.4 
Balance, June 26, 2020 337.0  $ 3.4  1.4  $   $ 3,360.7  $ 4,187.8  $ (156.6) $ 11.6 
Net earnings for the period —  —  —  —  —  225.8  —  — 
Dividends to common shareholders —  —  —  —  —  (23.6) —  — 
Mandatory convertible preferred stock cumulative dividends —  —  —  —  —  (17.3) —  — 
Other comprehensive income —  —  —  —  —  —  64.9  — 
Common stock-based award activity 0.2  —  —  —  31.0  —  —  — 
Change in noncontrolling interests —  —  —  —  —  —  —  0.4 
Balance, September 25, 2020 337.2  $ 3.4  1.4  $   $ 3,391.7  $ 4,372.7  $ (91.7) $ 12.0 

See the accompanying Notes to Consolidated Condensed Financial Statements.

8

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)
  Nine Months Ended
  October 1, 2021 September 25, 2020
Cash flows from operating activities:
Net earnings from continuing operations $ 444.8  $ 200.6 
Noncash items:
Amortization 235.4  232.7 
Depreciation 56.1  60.3 
Stock-based compensation expense 55.2  45.3 
Loss on extinguishment of debt 104.2   
Gain on investment in Vontier Corporation (57.0)  
Gain on litigation dismissal (26.0)  
Change in trade accounts receivable, net (20.4) 102.9 
Change in inventories (46.1) (14.2)
Change in trade accounts payable 14.8  (24.7)
Change in prepaid expenses and other assets (61.5) 23.2 
Change in accrued expenses and other liabilities 6.4  22.2 
Total operating cash provided by continuing operations 705.9  648.3 
Total operating cash provided by (used in) discontinued operations (19.4) 503.7 
Net cash provided by operating activities 686.5  1,152.0 
Cash flows from investing activities:
Cash paid for acquisitions, net of cash received (1,156.7) (15.2)
Payments for additions to property, plant and equipment (28.0) (58.9)
All other investing activities 1.1  5.3 
Total investing cash used in continuing operations (1,183.6) (68.8)
Total investing cash used in discontinued operations   (36.3)
Net cash used in investing activities (1,183.6) (105.1)
Cash flows from financing activities:
Net proceeds from (repayment of) commercial paper borrowings 215.0  (1,141.9)
Proceeds from borrowings (maturities greater than 90 days), net of issuance costs of $8 million in 2020
  741.7 
Repayment of borrowings (maturities greater than 90 days) (611.1) (250.0)
Payment of common stock cash dividend to shareholders (72.6) (70.7)
Payment of mandatory convertible preferred stock cash dividend to shareholders (34.5) (34.5)
All other financing activities 18.1  (0.6)
Total financing cash used in continuing operations (485.1) (756.0)
Total financing cash used in discontinued operations   (4.2)
Net cash used in financing activities (485.1) (760.2)
Effect of exchange rate changes on cash and equivalents (4.2) (2.7)
Net change in cash and equivalents (986.4) 284.0 
Beginning balance of cash and equivalents 1,824.8  1,205.2 
Ending balance of cash and equivalents $ 838.4  $ 1,489.2 
See the accompanying Notes to Consolidated Condensed Financial Statements.
9

Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOTE 1. BUSINESS OVERVIEW
Fortive Corporation (“Fortive,” the “Company,” “we,” “us,” or “our”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our well-known brands hold leading positions in intelligent operating solutions, precision technologies, and advanced healthcare solutions. Our businesses design, develop, service, manufacture, and market professional and engineered products, software, and services for a variety of end markets, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries across North America, Asia Pacific, Europe, and Latin America.
We prepared the unaudited consolidated condensed financial statements included herein in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) applicable for interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations; however, we believe the disclosures are adequate to make the information presented not misleading. The consolidated condensed financial statements included herein should be read in conjunction with the audited annual consolidated financial statements as of and for the year ended December 31, 2020 and the footnotes (“Notes”) thereto included within our 2020 Annual Report on Form 10-K.
In our opinion, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to fairly present our financial position as of October 1, 2021 and December 31, 2020, our results of operations for the three and nine month periods ended October 1, 2021 and September 25, 2020, and cash flows for the nine month periods ended October 1, 2021 and September 25, 2020. Reclassification of certain prior year amounts have been made to conform to current year presentation.
Vontier Separation and Discontinued Operations
On October 9, 2020 (the “Distribution Date”), the Company completed the separation of its Industrial Technologies segment by distributing 80.1% of the outstanding shares of Vontier Corporation (“Vontier”), the entity incorporated to hold such businesses, to Fortive stockholders (the “Vontier Separation”) on a pro rata basis. To effect the Vontier Separation, the Company distributed to its stockholders two shares of Vontier common stock for every five shares of the Company’s common stock outstanding held on September 25, 2020, the record date for the distribution, with the Company retaining 19.9% of the shares of Vontier common stock outstanding immediately following the Vontier Separation (the “Retained Vontier Shares”).
On the Distribution Date, Vontier paid the Company $1.8 billion, including $1.6 billion as part of the consideration for the contribution of certain assets and liabilities to Vontier by the Company in connection with the Vontier Separation and $202 million as an adjustment for excess cash balances remaining with Vontier (collectively, the “Cash Consideration”). We have used the Cash Consideration to repay certain outstanding indebtedness, make interest payments on certain debt instruments, and pay certain of the Company’s regular, quarterly cash dividends.
On January 19, 2021, we completed an exchange (the “Debt-for-Equity Exchange”) of 33.5 million shares of common stock of Vontier, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company held by Goldman Sachs & Co.
Refer to Note 11 of our 2020 Annual Report on Form 10-K and Note 6 to the consolidated condensed financial statements for the description of the debt repayments made subsequent to the Distribution Date. Interest expense and extinguishment costs related to the debt retired during the first quarter of 2021 are included in continuing operations.
The accounting requirements for reporting the Vontier business as a discontinued operation were met when the Vontier Separation was completed. Accordingly, the consolidated financial statements reflect the results of the Vontier business as a discontinued operation for all periods presented. Fortive did not retain a controlling interest in Vontier and therefore the Retained Vontier Shares were included in our assets of continuing operations as of December 31, 2020 and subsequent fair value changes in the Retained Vontier Shares prior to the Debt-for-Equity Exchange are included in our results from continuing operations for the nine month period ended October 1, 2021.
10

Table of Contents
Segment Presentation
In light of the Vontier Separation, we changed our internal reporting structure on the first day of the fourth quarter of 2020, September 26, 2020, to reflect organizational and leadership changes that allow us to better assess the operational performance of, and allocate resources to, our businesses. Our chief operating decision maker assesses performance and allocates resources based on our new operating segments, which are also our new reportable segments. Our new reportable segments are comprised of Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. All prior period segment information has been restated to reflect our new reportable segments.
Accumulated Other Comprehensive Income (Loss)
Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. We designated our ¥13.8 billion senior unsecured term facility loan and our Euro-denominated commercial paper outstanding during the nine month period ended September 25, 2020 as net investment hedges of our investment in certain foreign operations; we exited our Euro-denominated commercial paper positions during the second quarter of 2020 and repaid our ¥13.8 billion senior unsecured term facility loan during the fourth quarter of 2020. As of October 1, 2021 and December 31, 2020, we had no designated net investment hedges.
During the three and nine month periods ended September 25, 2020, we recognized foreign currency transaction losses of $2.0 million and gains of $2.0 million, respectively, on the debt that were deferred in the foreign currency translation component of Accumulated other comprehensive income (loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three and nine month periods ended September 25, 2020.
The changes in AOCI by component are summarized below ($ in millions):
Foreign
currency
translation
adjustments
Pension
adjustments (a)
Total
For the Three Months Ended October 1, 2021:
Balance, July 2, 2021 $ (72.1) $ (85.2) $ (157.3)
Other comprehensive income (loss) before reclassifications, net of income taxes (35.7)   (35.7)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)   1.2 
(b)
1.2 
Income tax impact   (0.3) (0.3)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes   0.9  0.9 
Net current period other comprehensive income (loss), net of income taxes (35.7) 0.9  (34.8)
Balance, October 1, 2021 $ (107.8) $ (84.3) $ (192.1)
For the Three Months Ended September 25, 2020:
Balance, June 26, 2020 $ (79.1) $ (77.5) $ (156.6)
Other comprehensive income (loss) before reclassifications, net of income taxes 63.9    63.9 
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)   1.2 
(b)
1.2 
Income tax impact   (0.2) (0.2)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes   1.0  1.0 
Net current period other comprehensive income (loss), net of income taxes 63.9  1.0  64.9 
Balance, September 25, 2020 $ (15.2) $ (76.5) $ (91.7)
11

Table of Contents
Foreign
currency
translation
adjustments
Pension adjustments (a)
Total
For the Nine Months Ended October 1, 2021:
Balance, December 31, 2020 $ (54.0) $ (87.1) $ (141.1)
Other comprehensive income (loss) before reclassifications, net of income taxes (53.8)   (53.8)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)   3.7 
(b)
3.7 
Income tax impact   (0.9) (0.9)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes   2.8  2.8 
Net current period other comprehensive income (loss) (53.8) 2.8  (51.0)
Balance, October 1, 2021 $ (107.8) $ (84.3) $ (192.1)
For the Nine Months Ended September 25, 2020:
Balance, December 31, 2019 $ 21.2  $ (77.5) $ (56.3)
Other comprehensive income (loss) before reclassifications, net of income taxes (36.4)   (36.4)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease)   1.2 
(b)
1.2 
Income tax impact   (0.2) (0.2)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes   1.0  1.0 
Net current period other comprehensive income (loss) (36.4) 1.0  (35.4)
Balance, September 25, 2020 $ (15.2) $ (76.5) $ (91.7)
(a) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans.
(b) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 8 for additional details).
Allowances for Doubtful Accounts
All trade accounts and unbilled receivables are reported in the Consolidated Condensed Balance Sheet adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management’s best estimate of the credit losses expected from our unbilled and trade accounts receivable portfolios over the life of the underlying assets. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances.

The following is a rollforward of the aggregated allowance for credit losses related to our trade accounts receivables as of October 1, 2021 ($ in millions):

Balance, December 31, 2020 $ 42.5 
Provision (0.4)
Write-offs (6.1)
Foreign currency exchange and other 0.3 
Balance, October 1, 2021 $ 36.3 
The allowance for unbilled receivables was immaterial for all periods presented.
Recently Issued Accounting Standard
In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity
12

Table of Contents
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which amends the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. We may adopt this standard using either a modified retrospective or a fully retrospective method of transition. This standard is effective for us beginning January 1, 2022. We are currently evaluating the impact of this standard on our financial statements and the method of adoption.
NOTE 2. ACQUISITIONS
We continually evaluate potential mergers, acquisitions, and divestitures that align with our strategy and expedite the evolution of our portfolio of businesses into new and attractive markets. We have completed a number of acquisitions that have been accounted for as business combinations and resulted in the recognition of goodwill in our financial statements. This goodwill arises because the purchase price for each acquired business reflects a number of factors, including the complementary fit, acceleration of our strategy and synergies the business brings with respect to our existing operations, the future earnings and cash flow potential of the business, the potential to add other strategically complementary acquisitions to the acquired business, the scarce or unique nature of the business in its markets, competition to acquire the business, the valuation of similar businesses in the marketplace (as reflected in a multiple of revenues, earnings, or cash flows), and the avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance our existing offerings to key target markets and develop new and profitable businesses.
We make an initial allocation of the purchase price at the date of acquisition based on our understanding of the fair value of the acquired assets and assumed liabilities. We obtain this information during due diligence and through other sources. In the months after closing, as we obtain additional information about these assets and liabilities, including through tangible and intangible asset appraisals, and learn more about the newly acquired business, we are able to refine the estimates of fair value and more accurately allocate the purchase price. Only items identified as of the acquisition date are considered for subsequent adjustment. We are in the process of obtaining valuations of certain acquired assets and evaluating the tax impact of certain acquisitions. We make appropriate adjustments to purchase price allocations prior to completion of the applicable measurement period, as required.
During the three and nine month periods ended October 1, 2021, immaterial adjustments were recorded to the preliminary purchase price allocation of acquisitions that closed during 2020.
Advanced Sterilization Products
On April 1, 2019 (the “Principal Closing Date”), we acquired the advanced sterilization products business (“ASP”) of Johnson & Johnson, a New Jersey corporation (“Johnson & Johnson”), for an aggregate purchase price of $2.7 billion (the “Transaction”), subject to certain post-closing adjustments set forth in a Stock and Asset Purchase Agreement, dated effective as of June 6, 2018 (the “Purchase Agreement”), between the Company and Ethicon, Inc., a New Jersey corporation (“Ethicon”) and a wholly owned subsidiary of Johnson & Johnson. ASP engages in the research, development, manufacture, marketing, distribution, and sale of low-temperature terminal sterilization and high-level disinfection products.
On the Principal Closing Date, we paid $2.7 billion in cash and obtained the transferred assets and assumed liabilities in 20 countries (“Principal Countries”), general patent and trademark assignments, and all transferred equity interests in ASP. ASP has operations in an additional 39 countries (“Non-Principal Countries”). The transferred assets and liabilities associated with these operations will close when requirements of country-specific agreements or regulatory approvals are satisfied.
The $2.7 billion purchase price was paid in exchange for ASP’s businesses in both Principal and Non-Principal Countries. As of October 1, 2021 we have closed 20 Principal Countries and 38 Non-Principal Countries that, in aggregate, accounted for approximately 99% of the preliminary valuation of ASP. The remaining Non-Principal Country represents less than 1% of the preliminary valuation of ASP, or $1.0 million, which is included as a prepaid asset in Other assets in the Consolidated Condensed Balance Sheet. As each Non-Principal Country closes, we reduce the prepaid asset and record the fair value of the assets acquired and liabilities assumed. All of the provisional goodwill associated with the Transaction is included in goodwill at October 1, 2021, and the majority of the provisional goodwill is tax deductible. There were no material measurement period adjustments recorded for the Non-Principal Countries during the three and nine month periods ended October 1, 2021.
In addition, the Company entered into a transition services agreement with Johnson & Johnson for certain administrative and operational services (“TSA”) and distribution agreements in the Non-Principal Countries. Under the distribution agreements, ASP sells finished goods to Ethicon at prices agreed by the parties. ASP recognizes these sales as revenue when the conditions for revenue recognition are met. Following the sale of finished goods by ASP, Ethicon obtains title of the finished goods, has full authority to sell and market the finished goods to end customers as it sees fit, and retains any revenue and profit from the sale. As of October 1, 2021, ASP had exited the TSAs and substantially all of the distribution agreements. ASP expects to close the remaining Non-Principal Country in the fourth quarter of 2021.
13

Table of Contents
Prior to our acquisition of ASP, Johnson & Johnson received a Civil Investigative Demand from the United States Department of Justice (“DOJ”) regarding a False Claims Act investigation arising from a whistleblower lawsuit pertaining to the pricing, quality, marketing, and promotion of certain of ASP’s products. Based on the totality of available information at the Principal Closing Date and throughout the applicable measurement period, management allocated $26 million of the $2.7 billion purchase price to a potential liability related to the aforementioned litigation. Following the Principal Closing Date, management continually evaluated the likelihood and magnitude of the asserted claims based on any new information that became available. In the second quarter of 2021, following the unsealing of the whistleblower lawsuit and DOJ’s declination to intervene in the litigation, the plaintiff dismissed the whistleblower lawsuit. Based on these developments, management derecognized the litigation liability from our Consolidated Condensed Balance Sheet and recorded the gain on litigation dismissal of $26 million within Non-operating income (expense), net in our Consolidated Condensed Statements of Earnings during the nine month period ended October 1, 2021.
ServiceChannel
On August 24, 2021, we acquired ServiceChannel Holdings, Inc. (“ServiceChannel”), a privately held, global provider of software as a service based multi-site facilities maintenance service solutions with an integrated service-provider network. The acquisition of ServiceChannel broadens our offering of software-enabled solutions for the facility and asset lifecycle workflow. The total consideration paid was approximately $1.2 billion, net of acquired cash, and includes approximately $36 million of deferred compensation consideration that will be recognized ratably over a twelve month service period. The ServiceChannel acquisition was primarily financed with available cash and proceeds from our financing activities. We preliminarily recorded approximately $897 million of goodwill related to the ServiceChannel acquisition, which is not tax deductible. ServiceChannel had revenue in 2020 of approximately $70 million and is an operating company within our Intelligent Operating Solutions segment.
The following table summarizes the preliminary estimated fair value of the assets acquired and liabilities assumed from ServiceChannel as of October 1, 2021 ($ in millions):
Goodwill $ 897.3 
Other intangible assets, primarily customer relationships, technology, database, and trade names 343.8 
Other assets and liabilities, net (82.4)
Net cash consideration $ 1,158.7 
Revenue and operating loss attributable to ServiceChannel for both the three and nine month periods ended October 1, 2021 were $10.1 million and $19.5 million, respectively, consistent with our expectations. The operating loss includes a combined $18.2 million of intangible asset amortization, acquisition-related fair value adjustments, and transaction and integration costs for both the three and nine month periods ended October 1, 2021. Transaction and integration related costs were approximately $13.2 million and are recorded in Selling, general and administration expenses, which are primarily comprised of compensation cost for employee retention bonuses and amounts paid to third-party advisors.
NOTE 3. DISCONTINUED OPERATIONS
On October 9, 2020, we completed the Vontier Separation. The accounting requirements for reporting the Vontier business as a discontinued operation were met when the Vontier Separation was completed. Accordingly, the consolidated financial statements reflect the results of the Vontier business as a discontinued operation for all periods presented.
Vontier Impairment Charge
As a result of the interim impairment testing performed, we concluded that the estimated fair value of the Telematics reporting unit was less than its carrying value as of March 27, 2020, and recorded a non-cash goodwill impairment charge of $85.3 million during the three month period ended March 27, 2020. The Telematics reporting unit was included in our former Industrial Technologies segment and part of the Vontier Separation. Accordingly, the impairment charge is recorded in Earnings from discontinued operations, net of income taxes in the Consolidated Statement of Earnings.
14

Table of Contents
The key components of income from discontinued operations for the three and nine month periods ended October 1, 2021 and September 25, 2020 were as follows ($ in millions):
Three Months Ended Nine Months Ended
  October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales $   $ 746.7  $   $ 1,889.6 
Cost of sales   (415.3)   (1,064.2)
Selling, general and administrative expenses (0.3) (127.1) (3.5) (380.7)
Research and development expenses   (31.6)   (94.7)
Goodwill impairment       (85.3)
Interest expense and other income, net   (7.0) 0.1  (19.3)
Earnings before income taxes (0.3) 165.7  (3.4) 245.4 
Income taxes   (25.9) 0.5  (48.3)
Net earnings from discontinued operations $ (0.3) $ 139.8  $ (2.9) $ 197.1 
The following table summarizes the major classes of assets and liabilities of discontinued operations that were included in the Company’s Consolidated Balance Sheets ($ in millions):
  October 1, 2021 December 31, 2020
ASSETS
Other current assets $   $ 30.4 
Total assets, discontinued operations $   $ 30.4 
LIABILITIES
Current liabilities:
Accrued expenses and other current liabilities $ (1.2) $ (33.3)
Total liabilities, discontinued operations $ (1.2) $ (33.3)
NOTE 4. GOODWILL AND OTHER INTANGIBLES
The following is a rollforward of our carrying value of goodwill by segment ($ in millions):
Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Total Goodwill
Balance, December 31, 2020 $ 3,268.8  $ 1,867.9  $ 2,222.5  $ 7,359.2 
Measurement period adjustments for 2020 acquisitions 0.5    (4.0) (3.5)
Attributable to 2021 acquisitions 897.3      897.3 
Foreign currency translation and other (13.3) (19.7) 1.5  (31.5)
Balance, October 1, 2021 $ 4,153.3  $ 1,848.2  $ 2,220.0  $ 8,221.5 
The increase in the goodwill balance of the Intelligent Operating Solutions segment for the nine month period ended October 1, 2021 is a result of the ServiceChannel acquisition. Refer to Note 2 for more information.
During the three and nine month periods ended October 1, 2021, we identified no triggering events indicating a potential impairment of goodwill.
15

Table of Contents
The following summarizes the gross carrying value and accumulated amortization for each major category of intangible asset ($ in millions):
October 1, 2021 December 31, 2020
Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization
Finite-lived intangibles:
Patents and technology $ 1,051.8  $ (449.4) $ 983.3  $ (401.1)
Customer relationships and other intangibles 3,106.5  (1,008.8) 2,958.3  (896.8)
Trademarks and trade names 67.2  (2.3) 18.0  (1.4)
Total finite-lived intangibles 4,225.5  (1,460.5) 3,959.6  (1,299.3)
Indefinite-lived intangibles:
Trademarks and trade names 627.0  —  630.3  — 
Total intangibles $ 4,852.5  $ (1,460.5) $ 4,589.9  $ (1,299.3)
Finite-lived intangible assets are amortized over the shorter of their legal or estimated useful lives.
During the three and nine month periods ended October 1, 2021, we acquired finite-lived intangible assets, consisting primarily of customer relationships, developed technology, and trade names, with a weighted average life of approximately 12 years as a result of the ServiceChannel Acquisition. Refer to Note 2 for additional information on the intangible assets acquired.
NOTE 5. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where our assets and liabilities are required to be carried at fair value, and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows:
Level 1 inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation.
Level 3 inputs are unobservable inputs based on our assumptions. The classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
Below is a summary of financial liabilities that are measured at fair value on a recurring basis ($ in millions):
Quoted Prices
in Active
Market
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
October 1, 2021
Deferred compensation liabilities $   $ 40.1  $   $ 40.1 
December 31, 2020
Investment in Vontier $ 1,119.2  $   $   $ 1,119.2 
Deferred compensation liabilities   34.8    34.8 
Certain management employees participate in our nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis, until after their termination of employment. All amounts deferred under such plans are unfunded, unsecured obligations and are presented as a component of our compensation and benefits accrual included in Other long-term liabilities in the Consolidated Condensed Balance Sheets. Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within our defined contribution plans for the benefit of U.S. employees (except that the earnings rates for amounts contributed unilaterally by the Company are entirely based on changes in the value of Fortive common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates.
16

Table of Contents
On October 9, 2020, we completed the Vontier Separation and retained 19.9% of the shares of Vontier common stock outstanding immediately following the Vontier Separation. We did not retain a controlling interest in Vontier and therefore the fair value of our Retained Vontier Shares were included in our assets of continuing operations as of December 31, 2020, and subsequent fair value changes are included in our results from continuing operations for the nine month period ended October 1, 2021.
On January 19, 2021, we completed the Debt-for-Equity Exchange of 33.5 million shares of common stock of Vontier, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company held by Goldman Sachs & Co., including (i) all $400.0 million of the 364-day delayed draw term loan due March 22, 2021 (the “Term Loan due March 2021”) and (ii) $683.2 million of the delayed-draw term loan due May 30, 2021 (the “Term Loan due May 2021”). The change in fair value of the Retained Vontier Shares and the resulting gain of $57.0 million was recorded in the nine month period ended October 1, 2021. We recorded a loss on extinguishment of the debt included in the Debt-for-Equity Exchange of $94.4 million in the nine month period ended October 1, 2021.
Nonrecurring Fair Value Measurements
Certain non-financial assets, primarily property, plant, and equipment, goodwill, and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets.
We evaluated events or circumstances that may indicate the carrying value of our non-financial assets may not be fully recoverable during the three and nine month periods ended October 1, 2021, and recorded no impairments.
Fair Value of Financial Instruments
The carrying amount and fair value of financial instruments are as follows ($ in millions):
October 1, 2021 December 31, 2020
Carrying Amount Fair Value Carrying Amount Fair Value
Current portion of long-term debt $ 1,143.2  $ 1,164.1  $ 1,399.8  $ 1,400.0 
Long-term debt, net of current maturities $ 1,442.1  $ 1,627.2  $ 2,830.3  $ 3,155.5 
As of October 1, 2021 and December 31, 2020, the current portion of long-term debt and long-term debt, net of current maturities were categorized as Level 1.
The fair values of the current portion of long-term debt and long-term debt were based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings may be attributable to changes in market interest rates and/or our credit ratings subsequent to the incurrence of the borrowing. The fair value of cash and cash equivalents, accounts receivable, net, and trade accounts payable, and commercial paper approximates their carrying amount due to the short-term maturities of these instruments.
NOTE 6. FINANCING AND CAPITAL
The carrying value of the components of our long-term debt were as follows ($ in millions):
October 1, 2021 December 31, 2020
3.15% senior unsecured notes due 2026
$ 894.9  $ 894.1 
4.30% senior unsecured notes due 2046
547.2  547.2 
0.875% senior convertible notes due 2022
1,143.2  1,389.0 
Term Loan due May 2021   1,000.0 
Term Loan due March 2021   399.8 
Long-term debt 2,585.3  4,230.1 
Less: current portion of long-term debt 1,143.2  1,399.8 
Long-term debt, net of current maturities $ 1,442.1  $ 2,830.3 
Aggregate unamortized debt discounts, premiums, and issuance costs of $21 million and $57 million as of October 1, 2021 and December 31, 2020, respectively, are netted against the principal amounts of the components of debt in the table above. Refer to Note 11 of our 2020 Annual Report on Form 10-K for further details of our debt financing.
17

Table of Contents
Debt-for-Equity Exchange
On January 19, 2021, we completed the Debt-for-Equity Exchange of 33.5 million shares of common stock of Vontier, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company held by Goldman Sachs & Co., including (i) all $400.0 million of the Term Loan due March 2021 and (ii) $683.2 million of the Term Loan due May 2021. We recorded a loss on extinguishment of the debt included in the Debt-for-Equity Exchange of $94.4 million in the nine month period ended October 1, 2021.
Term Loan due May 2021
On January 21, 2021, we repaid the remaining $316.8 million outstanding of the Term Loan due May 2021 from the cash proceeds received from Vontier in the Vontier Separation. The fees associated with the prepayment were immaterial.
Convertible Senior Notes
On February 22, 2019, we issued $1.4 billion in aggregate principal amount of our 0.875% Convertible Senior Notes due 2022 (the “Convertible Notes”), including $187.5 million in aggregate principal amount resulting from an exercise in full of an over-allotment option. The Convertible Notes were issued in a private placement to certain initial purchasers for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act.
The Convertible Notes bear interest at a rate of 0.875% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2019. The Convertible Notes mature on February 15, 2022, unless earlier repurchased or converted in accordance with their terms prior to such date.
As a result of the Vontier Separation and in accordance with the anti-dilution provisions of the Convertible Notes, effective October 9, 2020, the Convertible Notes are convertible into shares of our common stock at an adjusted conversion rate of 10.9568 shares per $1,000 principal amount of Convertible Notes (which is equivalent to an initial conversion price of $91.27 per share), subject to future adjustment upon the occurrence of certain events. The conversion rate is subject to customary anti-dilution adjustments. If certain corporate events occur prior to the maturity date, the conversion rate will be increased for a holder that elects to convert its Convertible Notes in connection with such corporate event. Upon conversion of the Convertible Notes, holders will receive cash, shares of our common stock, or a combination thereof, at our election. Our intention is to settle such conversions through cash up to the principal amount of the Convertible Notes and, if applicable, through shares of our common stock for conversion value, if any, in excess of the principal amount of the Convertible Notes.
Of the $1.4 billion in principal amount from the issuance of the Convertible Notes, $1.3 billion was classified as debt and $102.2 million was classified as equity, using an assumed effective interest rate of 3.38%. Debt issuance costs of $24.3 million were proportionately allocated to debt and equity.
On February 9, 2021, we repurchased $281 million of the Convertible Notes at fair value using the remaining cash proceeds received from Vontier in the Vontier Separation and other cash on hand. In connection with the repurchase, we recorded a loss on debt extinguishment during the nine month period ended October 1, 2021 of $10.5 million. In addition, upon repurchase we recorded $11.6 million as a reduction to additional paid-in capital related to the equity component of the repurchased Convertible Notes.
We recognized $11.1 million and $34.5 million in interest expense during the three and nine month periods ended October 1, 2021, respectively, of which $2.5 million and $7.9 million was related to the contractual coupon rate of 0.875%, $1.5 million and $4.7 million was attributable to the amortization of debt issuance costs and $7.1 million and $21.9 million was attributable to the amortization of the discount for each respective period. We recognized $13.6 million and $40.6 million in interest expense during the three and nine month periods ended September 25, 2020, respectively, of which $3.2 million and $9.5 million related to the contractual coupon rate of 0.875%, $1.8 million and $5.6 million was attributable to the amortization of debt issuance costs, and $8.6 million and $25.5 million was attributable to the amortization of the discount for each respective period. The discount at issuance was $102.2 million and is being amortized over a three-year period. The unamortized discount at October 1, 2021 was $11.0 million.
Prior to November 15, 2021, the Convertible Notes will be convertible only upon the occurrence of certain events and will be convertible thereafter at any time until the close of business on the business day immediately preceding the maturity date of the Convertible Notes.
18

Table of Contents
Classification of Debt Due within the Next Twelve Months
Our Convertible Senior Notes are recorded in the Current portion of long-term debt line item in the Consolidated Condensed Balance Sheet as of October 1, 2021.
Other Liquidity Sources
We generally satisfy any short-term liquidity needs that are not met through operating cash flows and available cash primarily through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”). Under these programs, we may issue unsecured promissory notes with maturities not exceeding 397 and 183 days, respectively.
Due to the volatility and disruption in the commercial paper markets during the first six months of 2020, we temporarily reduced our reliance on this source of funding, and consequently paid down and refinanced our outstanding commercial paper with the Term Loan due March 2021 that was retired in the Debt-for-Equity Exchange. In August 2021, we resumed borrowing under our Commercial Paper Program to fund, in part, the ServiceChannel acquisition.
Interest expense on commercial paper is paid at maturity and is generally based on our credit ratings at the time of issuance and prevailing short-term interest rates.

The details of our outstanding Commercial Paper Programs as of October 1, 2021 were as follows ($ in millions):
Carrying value Annual effective rate Weighted average remaining maturity (in days)
U.S. dollar-denominated commercial paper $ 215.0  0.19  % 12
Credit support for the Commercial Paper Programs is provided by a five-year $2.0 billion senior unsecured revolving credit facility that expires on November 30, 2023 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit support for our commercial paper programs, can also be used for working capital and other general corporate purposes. As of October 1, 2021, no borrowings were outstanding under the Revolving Credit Facility.
NOTE 7. SALES
We derive revenues primarily from the sale of products, software, and services. Revenue is recognized when control of promised products, software, or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products, software, or services. 
Sales of products and software includes revenues from the sale of products and equipment, software product offerings, and equipment rentals.
Sales of services includes revenues from extended warranties, post-contract customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, and services related to previously sold products.
Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only subject to the passage of time. Contract assets were $77 million as of October 1, 2021 and $56 million as of December 31, 2020.
Contract Costs — We incur direct incremental costs to obtain certain contracts, typically sales-related commissions and costs associated with assets used by our customers in certain software arrangements. Deferred sales-related commissions are generally not capitalized as the amortization period is one year or less, and we elected to use the practical expedient to expense these sales commissions as incurred. As of October 1, 2021 and December 31, 2020, we had $28 million and $31 million, respectively, in net revenue-related contract assets primarily related to certain software contracts. Revenue-related contract assets are recorded in the Prepaid expenses and other current assets and Other assets line items in our Condensed Consolidated Balance Sheets. These assets have estimated useful lives between 3 and 8 years.
Impairment losses recognized on our revenue-related contract assets were immaterial during the three and nine month periods ended October 1, 2021 and September 25, 2020.
Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to PCS and extended warranty sales, where in most cases we receive up-front payment and recognize revenue over the support term. We classify deferred revenue as
19

Table of Contents
current or noncurrent based on the timing of when we expect to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Consolidated Condensed Balance Sheets.
Our contract liabilities consisted of the following ($ in millions):
October 1, 2021 December 31, 2020
Deferred revenue - current $ 400.5  $ 376.4 
Deferred revenue - noncurrent 30.8  34.2 
Total contract liabilities $ 431.3  $ 410.6 
During the three and nine month periods ended October 1, 2021, we recognized revenue related to our contract liabilities at December 31, 2020 of $82 million and $270 million, respectively. The change in our contract liabilities from December 31, 2020 to October 1, 2021 was primarily due to the timing of cash receipts and sales of PCS and extended warranty services.
Remaining Performance Obligations — Our remaining performance obligations represent the transaction price of firm, noncancelable orders, with expected delivery dates to customers greater than one year from October 1, 2021, for which work has not been performed. We have excluded performance obligations with an original expected duration of one year or less from the amounts below.
The aggregate performance obligations attributable to each of our segments is as follows ($ in millions):
October 1, 2021
Intelligent Operating Solutions $ 109.4 
Precision Technologies 25.9 
Advanced Healthcare Solutions 7.9 
Total remaining performance obligations $ 143.2 
The majority of remaining performance obligations are related to service and support contracts, which we expect to fulfill approximately 55 percent within the next two years, approximately 85 percent within the next three years, and substantially all within four years.
20

Table of Contents
Disaggregation of Revenue
We disaggregate revenue from contracts with customers by sales of products and software and services, geographic location, and end market for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. Disaggregation of revenue for the three month period ended October 1, 2021 is presented as follows ($ in millions):
Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions    
Sales:
Sales of products and software $ 1,105.6  $ 462.7  $ 401.0  $ 241.9 
Sales of services 193.9  72.7  54.7  66.5 
Total $ 1,299.5  $ 535.4  $ 455.7  $ 308.4 
Geographic:
United States $ 683.7  $ 283.8  $ 234.6  $ 165.3 
China 154.8  48.8  75.8  30.2 
All other (each country individually less than 5% of total sales) 461.0  202.8  145.3  112.9 
Total $ 1,299.5  $ 535.4  $ 455.7  $ 308.4 
End markets:(a)
Direct sales:
  Medical $ 327.6  $ 10.5  $ 30.7  $ 286.4 
  Industrial & Manufacturing 313.5  204.4  103.2  5.9 
  Utilities & Power 97.3  55.3  42.0   
  Government 100.1  54.6  33.4  12.1 
  Communication, Electronics & Semiconductor 103.4  30.6  72.3  0.5 
  Aerospace & Defense 60.6    60.6   
  Oil & Gas 64.6  62.4  2.2   
  Retail & Consumer 52.1  31.5  20.6   
  Other 117.7  56.5  61.1  0.1 
     Total direct sales 1,236.9  505.8  426.1  305.0 
Distributors 62.6  29.6  29.6  3.4 
Total $ 1,299.5  $ 535.4  $ 455.7  $ 308.4 
(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.
21

Table of Contents
Disaggregation of revenue for the three month period ended September 25, 2020 is presented as follows ($ in millions):
Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions    
Sales:
Sales of products and software $ 988.1  $ 409.3  $ 366.2  $ 212.6 
Sales of services 171.7  49.8  52.3  69.6 
Total $ 1,159.8  $ 459.1  $ 418.5  $ 282.2 
Geographic:
United States $ 610.6  $ 241.1  $ 213.9  $ 155.6 
China 142.0  43.2  71.0  27.8 
All other (each country individually less than 5% of total sales) 407.2  174.8  133.6  98.8 
Total $ 1,159.8  $ 459.1  $ 418.5  $ 282.2 
End markets:(a)
Direct sales:
  Medical $ 304.7  $ 9.2  $ 29.7  $ 265.8 
  Industrial & Manufacturing 259.8  168.6  86.1  5.1 
  Utilities & Power 89.1  51.1  38.0   
  Government 86.2  42.3  36.4  7.5 
  Communications, Electronics & Semiconductor 73.2  28.8  43.9  0.5 
  Aerospace & Defense 66.3  8.6  57.7   
  Oil & Gas 54.7  52.5  2.2   
  Retail & Consumer 39.1  20.4  18.7   
  Other 117.6  52.4  65.2   
     Total direct sales 1,090.7  433.9  377.9  278.9 
Distributors 69.1  25.2  40.6  3.3 
Total $ 1,159.8  $ 459.1  $ 418.5  $ 282.2 
(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.
22

Table of Contents
Disaggregation of revenue for the nine month period ended October 1, 2021 is presented as follows ($ in millions):
Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions    
Sales:
Sales of products and software $ 3,318.8  $ 1,394.1  $ 1,211.6  $ 713.1 
Sales of services 559.6  194.0  163.4  202.2 
Total $ 3,878.4  $ 1,588.1  $ 1,375.0  $ 915.3 
Geographic:
United States $ 1,976.1  $ 808.7  $ 690.0  $ 477.4 
China 482.6  162.0  234.3  86.3 
All other (each country individually less than 5% of total sales) 1,419.7  617.4  450.7  351.6 
Total $ 3,878.4  $ 1,588.1  $ 1,375.0  $ 915.3 
End markets:(a)
Direct sales:
  Medical $ 983.0  $ 28.3  $ 99.6  $ 855.1 
  Industrial & Manufacturing 927.9  601.6  308.6  17.7 
  Utilities & Power 290.0  166.8  123.2   
  Government 287.0  150.7  105.7  30.6 
  Communication, Electronics & Semiconductor 288.8  90.9  196.2  1.7 
  Aerospace & Defense 181.7    181.7   
  Oil & Gas 194.6  186.9  7.7   
  Retail & Consumer 142.2  73.7  68.5   
  Other 379.9  184.3  195.5  0.1 
     Total direct sales 3,675.1  1,483.2  1,286.7  905.2 
Distributors 203.3  104.9  88.3  10.1 
Total $ 3,878.4  $ 1,588.1  $ 1,375.0  $ 915.3 
(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.
23

Table of Contents
Disaggregation of revenue for the nine month period ended September 25, 2020 is presented as follows ($ in millions):
Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions    
Sales:
Sales of products and software $ 2,820.6  $ 1,189.4  $ 1,036.6  $ 594.6 
Sales of services 488.9  149.4  150.5  189 
Total $ 3,309.5  $ 1,338.8  $ 1,187.1  $ 783.6 
Geographic:
United States $ 1,773.8  $ 710.7  $ 616.4  $ 446.7 
China 391.5  130.4  192.5  68.6 
All other (each country individually less than 5% of total sales) 1,144.2  497.7  378.2  268.3 
Total $ 3,309.5  $ 1,338.8  $ 1,187.1  $ 783.6 
End markets:(a)
Direct sales:
  Medical $ 849.1  $ 28.7  $ 84.5  $ 735.9 
  Industrial & Manufacturing 750.7  490.3  244.8  15.6 
  Utilities & Power 257.1  148.6  108.5   
  Government 244.0  119.6  102.6  21.8 
  Communications, Electronics & Semiconductor 201.0  79.8  119.9  1.3 
  Aerospace & Defense 179.5  15.4  164.1   
  Oil & Gas 164.3  155.4  8.9   
  Retail & Consumer 123.1  64.3  58.8   
  Other 342.2  163.3  178.9   
     Total direct sales 3,111.0  1,265.4  1,071.0  774.6 
Distributors 198.5  73.4  116.1  9.0 
Total $ 3,309.5  $ 1,338.8  $ 1,187.1  $ 783.6 
(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.
24

Table of Contents
NOTE 8. PENSION PLANS
For a full description of our noncontributory defined benefit pension plans refer to Note 12 of our 2020 Annual Report on Form 10-K.
The following sets forth the components of our net periodic costs associated with our noncontributory defined benefit pension plans ($ in millions):
  Three Months Ended Nine Months Ended
  October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
U.S. Pension Benefits:
Interest cost $ 0.3  $ 0.3  $ 0.7  $ 0.9 
Expected return on plan assets (0.3) (0.3) (0.7) (0.9)
Net periodic pension cost $   $   $   $  
Non-U.S. Pension Benefits:
Service cost $ 1.0  $ 1.1  $ 3.0  $ 3.3 
Interest cost 0.7  1.0  2.3  3.0 
Expected return on plan assets (1.3) (1.4) (3.9) (4.0)
Amortization of net loss 1.0  1.1  3.2  3.1 
Amortization of prior service cost 0.1  0.1  0.3  0.3 
Net periodic pension cost $ 1.5  $ 1.9  $ 4.9  $ 5.7 

We report all components of net periodic pension costs, with the exception of service costs, in other non-operating expenses as a component of non-operating income in the Consolidated Condensed Statements of Earnings. Service costs are reported in cost of sales and selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings according to the classification of the participant’s compensation.
Employer Contributions
During 2021, our cash contribution requirements for our non-U.S. and U.S. defined benefit plans for Fortive’s pension plans are expected to be approximately $11 million and $1 million, respectively. The actual amounts to be contributed depend upon, among other things, legal requirements, underlying asset returns, the plan’s funded status, the anticipated tax deductibility of the contribution, local practices, market conditions, interest rates, and other factors.
NOTE 9. INCOME TAXES

Our effective tax rate for the three and nine month periods ended October 1, 2021 was 13.2% and 11.1% as compared to 13.4% and 17.7%, respectively, for the three and nine month periods ended September 25, 2020. The effective tax rate for the three month period ended October 1, 2021 was relatively consistent with the effective tax rate for the three month period ended September 25, 2020. The year-over-year decrease in the effective tax rate for the nine month period ended October 1, 2021 as compared to the nine month period ended September 25, 2020 was due primarily to a permanent difference on the gain on our Retained Vontier Shares due to the tax-free treatment of our disposition of the shares through the Debt-for-Equity Exchange, a reduction to our uncertain tax positions, and increases in certain federal tax benefits for the nine month period ended October 1, 2021. Additionally, the tax costs incurred during the nine month period ended September 25, 2020 associated with the repatriation of a portion of our previously reinvested earnings outside of the United States contributed to the year-over year decrease in the effective tax rate for the nine month period ended October 1, 2021.
Our effective tax rate for the three and nine month periods ended October 1, 2021 differs from the U.S. federal statutory rate of 21% due primarily to the positive and negative effects of the Tax Cuts and Jobs Act, U.S. federal permanent differences, the impact of credits and deductions provided by law, and a reduction in our uncertain tax positions. Specific to the nine month period ended October 1, 2021, our effective tax rate also differs from the U.S. federal statutory rate of 21% due to a permanent difference on the gain on our Retained Vontier Shares due to the tax-free treatment of our disposition of the shares through the Debt-for-Equity Exchange. Specific to the nine month period ended September 25, 2020, our effective tax rate also differs from the U.S. federal statutory rate of 21% due to the repatriation of a portion of our previously reinvested earnings outside of the United States.
25

Table of Contents
NOTE 10. STOCK-BASED COMPENSATION
Our stock-based compensation program (the “Stock Plan”) provides for the grant of stock appreciation rights, performance stock units, restricted stock units, restricted stock awards, and performance stock awards (collectively, “Stock Awards”), stock options, or any other stock-based award. As of October 1, 2021, approximately 19 million shares of our common stock were available for subsequent issuance under the Stock Plan. For a full description of our stock-based compensation program refer to Note 17 of our 2020 Annual Report on Form 10-K.
Stock-based Compensation Expense
Stock-based compensation has been recognized as a component of Selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings based on the portion of the awards that are ultimately expected to vest.
The following summarizes the components of our stock-based compensation expense under the Stock Plan ($ in millions):
  Three Months Ended Nine Months Ended
  October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Stock Awards:
Pretax compensation expense $ 11.3  $ 9.5  $ 34.0  $ 27.7 
Income tax benefit (2.1) (1.7) (5.9) (4.6)
Stock Award expense, net of income taxes 9.2  7.8  28.1  23.1 
Stock options:
Pretax compensation expense 7.1  6.1  21.2  17.6 
Income tax benefit (1.3) (0.8) (3.8) (2.6)
Stock option expense, net of income taxes 5.8  5.3  17.4  15.0 
Total stock-based compensation:
Pretax compensation expense 18.4  15.6  55.2  45.3 
Income tax benefit (3.4) (2.5) (9.7) (7.2)
Total stock-based compensation expense, net of income taxes $ 15.0  $ 13.1  $ 45.5  $ 38.1 
The following summarizes the unrecognized compensation cost for the Stock Plan awards as of October 1, 2021. This compensation cost is expected to be recognized over a weighted average period of approximately two years, representing the remaining service period related to the awards. Future compensation amounts will be adjusted for any changes in estimated forfeitures ($ in millions):
Stock Awards $ 89.6 
Stock options 55.2 
Total unrecognized compensation cost $ 144.8 


26

Table of Contents
NOTE 11. COMMITMENTS AND CONTINGENCIES
For a description of our litigation and contingencies and additional information about our leases, refer to Note 16 and Note 10, respectively, in our 2020 Annual Report on Form 10-K.
Warranty
We generally accrue estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and, in certain instances, estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known.
The following is a rollforward of our accrued warranty liability ($ in millions):
Balance, December 31, 2020 $ 24.9 
Accruals for warranties issued during the period 13.0 
Settlements made (12.1)
Balance, October 1, 2021 $ 25.8 
Leases
Operating lease cost for the three month periods ended October 1, 2021 and September 25, 2020 was $15 million and $14 million, respectively. Operating lease cost for the nine month periods ended October 1, 2021 and September 25, 2020 was $45 million and $44 million, respectively. During the nine month periods ended October 1, 2021 and September 25, 2020, cash paid for operating leases included in operating cash flows was $40 million and $37 million, respectively. Right-of-use assets obtained in exchange for operating lease obligations were $24 million and $34 million during the nine month periods ended October 1, 2021 and September 25, 2020, respectively.
NOTE 12. NET EARNINGS PER SHARE
Basic net earnings per share (“EPS”) is calculated by dividing net earnings attributable to common stockholders by the weighted average number of shares of common stock outstanding for the applicable period. Diluted EPS is similarly calculated, except that the calculation includes the dilutive effect of the assumed issuance of shares under stock-based compensation plans under the treasury stock method, except where the inclusion of such shares would have an anti-dilutive impact. Anti-dilutive options excluded from the diluted EPS calculation for the three month periods ended October 1, 2021 and September 25, 2020 were 0.2 million and 5.3 million, respectively. There were 0.3 million and 5.5 million anti-dilutive options excluded for the nine month periods ended October 1, 2021 and September 25, 2020, respectively.
As described in Note 6, upon conversion of the Convertible Notes, holders will receive cash, shares of our common stock, or a combination thereof, at our election. Our intention is to settle such conversions through cash up to the principal amount of the Convertible Notes and, if applicable, through shares of our common stock for conversion value, if any, in excess of the principal amount of the Convertible Notes. We believe we have the ability to settle these obligations as intended, and therefore we have accounted for the conversion features under the treasury stock method in our calculation of EPS. Because the fair value of our common stock is below the conversion price, the Convertible Notes had no impact on our earnings per share for the three and nine month periods ended October 1, 2021 and September 25, 2020.
On July 1, 2021, all outstanding shares of our 5.0% Mandatory Convertible Preferred Stock (“MCPS”) converted at a rate of 14.0978 common shares per share of preferred stock into an aggregate of approximately 19.4 million shares (net of fractional shares) of the Company’s common stock, pursuant to the terms of the Certificate of Designation governing the Series A Preferred Stock. Fortive issued cash in lieu of fractional shares of common stock in the conversion. These payments were recorded as a reduction to additional paid-in capital. The final dividend of $12.50 per share, or $17.2 million in the aggregate, was paid on July 1, 2021. The impact of the MCPS calculated under the if-converted method was anti-dilutive for the periods in 2021 prior to conversion.
27

Table of Contents
Information related to the calculation of net earnings per share of common stock is summarized as follows ($ and shares in millions, except per share amounts):
Three Months Ended Nine Months Ended
  October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Numerator
Net earnings from continuing operations $ 151.1  $ 86.0  $ 444.8  $ 200.6 
Mandatory convertible preferred stock cumulative dividends   (17.3) (34.5) (51.8)
Net earnings attributable to common stockholders from continuing operations $ 151.1  $ 68.7  $ 410.3  $ 148.8 
Denominator
Weighted average common shares outstanding used in basic earnings per share 358.9  337.6  345.6  337.3 
Incremental common shares from:
Assumed exercise of dilutive options and vesting of dilutive Stock Awards 3.3  3.2  3.2  2.9 
Weighted average common shares outstanding used in diluted earnings per share 362.2  340.8  348.8  340.2 
Net earnings from continuing operations per common share - Basic $ 0.42  $ 0.20  $ 1.19  $ 0.44 
Net earnings from continuing operations per common share - Diluted $ 0.42  $ 0.20  $ 1.18  $ 0.44 
We declared and paid cash dividends per common share for the periods as presented below. We declared and paid the MCPS dividend in the first quarter of 2021, and declared and paid the final dividend in the second quarter of 2021, while the MCPS dividends for the first, second and third quarter of 2020 were declared, accrued, and paid as follows:
Dividend Per
Common Share
Amount
($ in millions)
Dividend per MCPS Amount
($ in millions)
2021:
First quarter $ 0.07  $ 23.7  $ 12.5  $ 17.3 
Second quarter 0.07  23.7  12.5  17.2 
Third quarter 0.07  25.2     
Total $ 0.21  $ 72.6  $ 25.0  $ 34.5 
2020:
First quarter $ 0.07  $ 23.5  $ 12.5  $ 17.3 
Second quarter 0.07  23.6  12.5  17.2 
Third quarter 0.07  23.6  12.5  17.3 
Total $ 0.21  $ 70.7  $ 37.5  $ 51.8 
* The sum of the components of total dividends paid may not equal the total amount due to rounding.
The first quarter 2020 MCPS dividends were paid on April 1, 2020, the second quarter 2020 MCPS dividends were paid on July 1, 2020, and the third quarter 2020 MCPS dividends were paid on October 1, 2020.

28

Table of Contents
NOTE 13. SEGMENT INFORMATION
We report our results in three separate business segments consisting of Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. Our chief operating decision maker assesses performance and allocates resources based on our operating segments, which are also our reportable segments. Operating profit amounts in the Other category consist of unallocated corporate costs and other costs not considered part of our evaluation of reportable segment operating performance. Our segment results are as follows ($ in millions):
  Three Months Ended Nine Months Ended
  October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales:
Intelligent Operating Solutions $ 535.4  $ 459.1  $ 1,588.1  $ 1,338.8 
Precision Technologies 455.7  418.5  1,375.0  1,187.1 
Advanced Healthcare Solutions 308.4  282.2  915.3  783.6 
Total $ 1,299.5  $ 1,159.8  $ 3,878.4  $ 3,309.5 
Operating Profit:
Intelligent Operating Solutions $ 90.0  $ 77.5  $ 313.4  $ 213.0 
Precision Technologies 101.1  82.1  301.1  232.7 
Advanced Healthcare Solutions 34.4  1.8  75.8  (15.9)
Other (24.7) (23.8) (80.6) (74.2)
Total Operating Profit 200.8  137.6  609.7  355.6 
Interest expense, net (25.1) (36.9) (78.0) (111.7)
Loss on extinguishment of debt     (104.9)  
Gain on investment in Vontier Corporation     57.0   
Gain on litigation dismissal     26.0   
Other non-operating expense, net (1.6) (1.4) (9.5) (0.3)
Earnings from continuing operations before income taxes $ 174.1  $ 99.3  $ 500.3  $ 243.6 

29

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Fortive Corporation (“Fortive,” the “Company,” “we,” “us,” or “our”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our well-known brands hold leading positions in intelligent operating solutions, precision technologies, and advanced healthcare solutions. Our businesses design, develop, service, manufacture, and market professional and engineered products, software, and services for a variety of end markets, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries across North America, Asia Pacific, Europe, and Latin America.
On October 9, 2020 (the “Distribution Date”), the Company completed the separation of its Industrial Technologies segment by distributing 80.1% of the outstanding shares of Vontier Corporation (“Vontier”), the entity incorporated to hold such businesses, to Fortive stockholders (the “Vontier Separation”) on a pro rata basis. To effect the Vontier Separation, the Company distributed to its stockholders two shares of Vontier common stock for every five shares of the Company’s common stock outstanding held on September 25, 2020, the record date for the distribution, with the Company retaining 19.9% of the shares of Vontier common stock outstanding immediately following the Vontier Separation (the “Retained Vontier Shares”).
On January 19, 2021, we completed an exchange (the “Debt-for-Equity Exchange”) of 33.5 million shares of Vontier common stock, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company held by Goldman Sachs & Co.
The accounting requirements for reporting the Vontier business as a discontinued operation were met when the Vontier Separation was completed. Accordingly, the consolidated financial statements reflect the results of the Vontier business as a discontinued operation for all periods presented. Fortive did not retain a controlling interest in Vontier and therefore the Retained Vontier Shares were included in our assets of continuing operations as of December 31, 2020 and subsequent fair value changes in the Retained Vontier Shares prior to the Debt-for-Equity Exchange are included in our results from continuing operations for the nine month period ended October 1, 2021.
This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide a reader of our financial statements with a narrative from the perspective of management. The following discussion should be read in conjunction with the MD&A and consolidated financial statements included in our 2020 Annual Report on Form 10-K. Our MD&A is divided into five sections:
Information Relating to Forward-Looking Statements
Overview
Results of Operations
Liquidity and Capital Resources
Critical Accounting Estimates
30

Table of Contents
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this quarterly report, in other documents we file with or furnish to the Securities and Exchange Commission (“SEC”), in our press releases, webcasts, conference calls, materials delivered to shareholders and other communications, are “forward-looking statements” within the meaning of the United States federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of revenue, expenses, profit, profit margins, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position or other financial measures; management’s plans and strategies for future operations, including statements relating to anticipated operating performance, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions, divestitures, strategic opportunities, securities offerings, stock repurchases, dividends and executive compensation; growth, declines and other trends in markets we sell into, including the expected impact of trade and tariff policies; new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; impact of changes to tax laws; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future. Terminology such as “believe,” “anticipate,” “should,” “could,” “intend,” “will,” “plan,” “expect,” “estimate,” “project,” “target,” “may,” “possible,” “potential,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words.
Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Important factors that could cause actual results to differ materially from those envisaged in the forward-looking statements include, among others, the following:
Risk Related to Our Business Operations
Significant uncertainty remains about how the COVID-19 pandemic may further impact our global operations and the operations of our customers, suppliers, and vendors.
Conditions in the global economy, the markets we serve and the financial markets may adversely affect our business and financial statements.
Our growth could suffer if the markets into which we sell our products and services decline, do not grow as anticipated, or experience cyclicality.
We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce prices for our products and services.
Our growth depends in part on the timely development and commercialization and customer acceptance of new and enhanced products and services based on technological innovation.
If we are unable to recruit and retain key employees, our business may be harmed.
A significant disruption in, or breach in security of, our information technology systems could adversely affect our business.
Defects and unanticipated use or inadequate disclosure with respect to our products (including software) or services could adversely affect our business, reputation, and financial statements.
Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns, or inventory levels of, key distributors and other channel partners could adversely affect our financial statements.
Our financial results are subject to fluctuations in the cost and availability of commodities or components that we use in our operations.
If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our profitability may suffer.
31

Table of Contents
Our reliance upon sole or limited sources of, or any delay in, supply for certain materials, components, and services could cause production interruptions, delays, and inefficiencies.
Our restructuring actions could have long-term adverse effects on our business.
Work stoppages, works council campaigns, and other labor disputes could adversely impact our productivity and results of operations.
If we suffer loss to our facilities, supply chains, distribution systems, or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
If we do not or cannot adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights.
Third parties may claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses, or licensing expenses or be prevented from selling products or services.
We are subject to a variety of litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our financial statements.
Risk Related to our International Operations
International economic, political, legal, compliance, and business factors could negatively affect our financial statements.
Trade relations between China and the United States could have a material adverse effect on our business and financial statements.
Foreign currency exchange rates may adversely affect our financial statements.
Risk Related to Our Acquisitions, Investments, and Dispositions
Any inability to consummate acquisitions at our anticipated rate and at appropriate prices could negatively impact our growth rate and stock price.
Our acquisition of businesses, joint ventures, and strategic relationships could negatively impact our financial statements.
The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we have sold could adversely affect our financial statements.
Potential indemnification liabilities to Vontier pursuant to the separation agreement could materially and adversely affect our businesses, financial condition, results of operations, and cash flows.
Risk Related to Regulatory and Compliance Matters
Changes in industry standards and governmental regulations may reduce demand for our products or services or increase our expenses.
Our reputation, ability to do business, and financial statements may be impaired by improper conduct by any of our employees, agents, or business partners.
Our operations, products, and services expose us to the risk of environmental, health, and safety liabilities, costs, and violations that could adversely affect our reputation and financial statements.
Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our financial statements and reputation.
32

Table of Contents
Risk Related to Our Tax and Accounting Matters
Changes in our effective tax rates or exposure to additional income tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods.
We could incur significant liability if the separation and distribution of Vontier is determined to be a taxable transaction.
Changes in U.S. generally accepted accounting principles in the United States (“GAAP”) could adversely affect our reported financial results and may require significant changes to our internal accounting systems and processes.
We may be required to recognize impairment charges for our goodwill and other intangible assets.
Risk Related to Our Financing Activities
We have incurred a significant amount of debt, and our debt will increase further if we incur additional debt and do not retire existing debt.
The interest rates on our credit facilities may be impacted by the phase out of the London Interbank Offered Rate.
Risk Related to Shareholder Rights
Certain provisions in our amended and restated certificate of incorporation and bylaws, and of Delaware law, may prevent or delay an acquisition of our company, which could decrease the trading price of our common stock.
Our amended and restated certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders, which could discourage lawsuits against us and our directors and officers.
See “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 for further discussion regarding reasons that actual results may differ materially from the results, developments, and business decisions contemplated by our forward-looking statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call, materials or other communication in which they are made (or such earlier date as may be specified in such statement). We do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
OVERVIEW
General
Fortive is a multinational business with global operations with approximately 47% of our sales derived from customers outside of the United States in 2020. As a company with global operations, our businesses are affected by worldwide, regional, and industry-specific economic and political factors. Our geographic and industry diversity, as well as the range of products, software, and services we offer, typically help limit the impact of any one industry or the economy of any single country (except for the United States) on our operating results. Given the broad range of products manufactured, software and services provided, and geographies served, we use general economic trends to predict the overall outlook for the Company. Our individual businesses monitor key competitors and customers, including their sales, to the extent possible, to gauge relative performance and the outlook for the future.
As a result of our geographic and industry diversity, we face a variety of opportunities and challenges, including technological development in most of the markets we serve, the expansion and evolution of opportunities in high growth markets, trends and costs associated with a global labor force, and consolidation of our competitors. We define high growth markets as developing markets of the world experiencing extended periods of accelerated growth in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America, and Asia with the exception of Japan and Australia. We operate in a highly competitive business environment in most markets, and our long-term growth and profitability will depend, in particular, on our ability to expand our business across geographies and market segments, identify, consummate, and integrate appropriate acquisitions, develop innovative and differentiated new products, services, and software, expand and improve the effectiveness of our sales force, continue to reduce costs and improve operating efficiency and quality, attract relevant talent and retain, grow, and empower our talented workforce, and effectively address the demands of an increasingly regulated environment. We are making significant investments, organically and through acquisitions, to address technological
33

Table of Contents
change in the markets we serve and to improve our manufacturing, research and development, and customer-facing resources in order to be responsive to our customers throughout the world.
ServiceChannel Acquisition
On August 24, 2021, we acquired ServiceChannel Holdings, Inc. (“ServiceChannel”), a privately held, global provider of software as a service (“SAAS”) based multi-site facilities maintenance service solutions with an integrated service-provider network. The acquisition of ServiceChannel broadens our offering of software-enabled solutions for the facility and asset lifecycle workflow. The total consideration paid was approximately $1.2 billion, net of acquired cash, and includes approximately $36 million of deferred compensation consideration that will be recognized ratably over a twelve month service period. The ServiceChannel acquisition was primarily financed with available cash and proceeds from our financing activities. We preliminarily recorded approximately $897 million of goodwill related to the ServiceChannel acquisition, which is not tax deductible. ServiceChannel had revenue in 2020 of approximately $70 million and is an operating company within our Intelligent Operating Solutions segment.
ASP Acquisition
On April 1, 2019 (the “Principal Closing Date”), we acquired the Advanced Sterilization Products business (“ASP”) of Johnson & Johnson, a New Jersey corporation (“Johnson & Johnson”) for an aggregate purchase price of $2.7 billion (the “Transaction”), subject to certain post-closing adjustments set forth in a Stock and Asset Purchase Agreement, dated effective as of June 6, 2018, between the Company and Ethicon, Inc., a New Jersey corporation (“Ethicon”) and a wholly owned subsidiary of Johnson & Johnson. ASP engages in the research, development, manufacture, marketing, distribution, and sale of low-temperature terminal sterilization and high-level disinfection products. Refer to Note 2 to the consolidated condensed financial statements for additional information regarding the Transaction.
Prior to our acquisition of ASP, Johnson & Johnson received a Civil Investigative Demand from the United States Department of Justice (“DOJ”) regarding a False Claims Act investigation arising from a whistleblower lawsuit pertaining to the pricing, quality, marketing, and promotion of certain of ASP’s products. Based on the totality of available information at the Principal Closing Date and throughout the applicable measurement period, management allocated $26 million of the $2.7 billion purchase price to a potential liability related to the aforementioned litigation. Following the Principal Closing Date, management continually evaluated the likelihood and magnitude of the asserted claims based on any new information that became available. In the second quarter of 2021, following the unsealing of the whistleblower lawsuit and DOJ’s declination to intervene in the litigation, the plaintiff dismissed the whistleblower lawsuit. Based on these developments, management derecognized the litigation liability from our Consolidated Condensed Balance Sheet and recorded the gain on litigation dismissal of $26 million within Non-operating income (expense), net in our Consolidated Condensed Statements of Earnings during the nine month period ended October 1, 2021.
Vontier Separation
On October 9, 2020 (the “Distribution Date”), the Company completed the separation of its Industrial Technologies segment by distributing 80.1% of the outstanding shares of Vontier Corporation (“Vontier”), the entity incorporated to hold such businesses, to Fortive stockholders (the “Vontier Separation”) on a pro rata basis. To effect the Vontier Separation, the Company distributed to its stockholders two shares of Vontier common stock for every five shares of the Company’s common stock outstanding held on September 25, 2020, the record date for the distribution, with the Company retaining 19.9% of the shares of Vontier common stock outstanding immediately following the Vontier Separation (the “Retained Vontier Shares”).
On the Distribution Date, Vontier paid the Company $1.8 billion, including $1.6 billion as part of the consideration for the contribution of certain assets and liabilities to Vontier by the Company in connection with the Vontier Separation and $202 million as an adjustment for excess cash balances remaining with Vontier (collectively, the “Cash Consideration”). We have used the Cash Consideration to repay certain outstanding indebtedness, make interest payments on certain debt instruments, and pay certain of the Company’s regular, quarterly cash dividends.
On January 19, 2021, we completed an exchange (the “Debt-for-Equity Exchange”) of 33.5 million shares of common stock of Vontier, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company held by Goldman Sachs & Co.
Refer to Note 11 of our 2020 Annual Report on Form 10-K and Note 6 to the consolidated condensed financial statements for the description of the debt repayments made subsequent to the Distribution Date. Interest expense and extinguishment costs related to the debt retired during the first quarter of 2021 are included in our results from continuing operations for the nine month period ended October 1, 2021.
34

Table of Contents
The accounting requirements for reporting the Vontier business as a discontinued operation were met when the Vontier Separation was completed. Accordingly, the consolidated condensed financial statements reflect the results of the Vontier business as a discontinued operation for all periods presented. Fortive did not retain a controlling interest in Vontier and therefore the Retained Vontier Shares were included in our assets of continuing operations as of December 31, 2020 and subsequent fair value changes in the Retained Vontier Shares prior to the Debt-for-Equity Exchange are included in our results from continuing operations for the nine month period ended October 1, 2021.
In connection with the Vontier Separation, Fortive and Vontier entered into various agreements to effect the Vontier Separation and provide a framework for Vontier’s relationship with Fortive after the Vontier Separation, including a transition services agreement, an employee matters agreement, a tax matters agreement, an intellectual property matters agreement, a Fortive Business System license agreement, and a stockholder’s and registration rights agreement (the “Agreements”). These Agreements govern the Vontier Separation between Fortive and Vontier of the assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) of Fortive and its subsidiaries attributable to periods prior to, at and after the Vontier Separation and also govern certain relationships between Fortive and Vontier after the Vontier Separation. The impact of these services on our consolidated condensed financial statements was immaterial.
Segment Presentation
In light of the Vontier Separation, we changed our internal reporting structure on the first day of the fourth quarter of 2020, September 26, 2020, to reflect organizational and leadership changes that allow us to better assess the operational performance of, and allocate resources to, our businesses. Our chief operating decision maker assesses performance and allocates resources based on our new operating segments, which are also our new reportable segments. Our new reportable segments are comprised of Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. All prior period segment information has been restated to reflect our new reportable segments.
Non-GAAP Measures
In this report, references to sales from existing businesses refer to sales from operations calculated according to generally accepted accounting principles in the United States (“GAAP”) but excluding (1) the impact from acquired businesses and (2) the impact of currency translation. References to sales attributable to acquisitions or acquired businesses refer to GAAP sales from acquired businesses recorded prior to the first anniversary of the acquisition and the effect of purchase accounting adjustments, less the amount of sales attributable to certain divested businesses or product lines not considered discontinued operations prior to the first anniversary of the divestiture. The portion of sales attributable to the impact of currency translation is calculated as the difference between (a) the period-to-period change in sales (excluding sales impact from acquired businesses) and (b) the period-to-period change in sales (excluding sales impact from acquired businesses) after applying the current period foreign exchange rates to the prior year period. Sales from existing businesses should be considered in addition to, and not as a replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies.
Management believes that reporting the non-GAAP financial measure of sales from existing businesses provides useful information to investors by helping identify underlying growth trends in our business and facilitating comparisons of our sales performance with our performance in prior and future periods and to our peers. We exclude the effect of acquisition and divestiture related items because the nature, size, and number of such transactions can vary dramatically from period to period and between us and our peers. We exclude the effect of currency translation from sales from existing businesses because the impact of currency translation is not under management’s control and is subject to volatility. Management believes the exclusion of the effect of acquisitions and divestitures and currency translation may facilitate the assessment of underlying business trends and may assist in comparisons of long-term performance.
Business Performance and Outlook
COVID-19 directly impacted our business and operating results during the three and nine month periods ended September 25, 2020, as we experienced a decline in demand from customers in nonessential end-markets and reduced demand resulting from macroeconomic disruption or disruption in adjacent end markets. Our results were severely impacted within certain geographies, most notably Asia in the first quarter of 2020, and North America and Europe in the second quarter of 2020, as virus control measures in varying magnitude were deployed in those geographies at varying times. As such, the year-over-year comparisons for the three and nine month periods ended October 1, 2021 reflect the greater detrimental impacts of COVID-19 on our 2020 results.
35

Table of Contents
Business Performance For the Period Ended October 1, 2021
Overall demand for our products and services has continued to accelerate during the three and nine month periods ended October 1, 2021, as the distribution and administration of vaccinations in developed countries has led to easing of virus control measures. For the three and nine month periods ended October 1, 2021, aggregate year-over-year sales increased 12.0% and 17.2%, respectively, and were largely driven by increased demand from our existing businesses. Sales from existing businesses increased 9.1% and 12.9% during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020, reflecting positive, broad-based momentum and focused execution across our portfolio, most notably within our short-cycle industrial and SAAS businesses.
Geographically, year-over-year sales from existing businesses in both high growth and developed markets increased at a high single-digit rate during three month period ended October 1, 2021, driven by high single-digit growth in North America and Europe, greater than 20% growth in Latin America, and mid-single-digit growth in Asia. During the nine month period ended October 1, 2021, year-over-year sales from existing businesses in developed and high growth markets increased at a low double-digit rate and at a rate in the mid-teens, respectively, driven by low double-digit growth in North America and Asia, growth at a rate in the mid-teens in Europe, and greater than 20% growth in Latin America.
Year-over-year price increases contributed 2.2% and 1.5% to sales growth during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020, and is reflected as a component of the change in sales from existing businesses. For the three month period ended October 1, 2021, price increases outpaced material cost increases.
During the third quarter of 2021, widespread supply chain challenges due to labor, raw material, and component shortages as well as logistics issues with port congestion affected multiple industries and raised material and shipping costs. Our supply chain was largely responsive to these dynamics and we successfully implemented solutions to effectively support our near-term operations, countermeasure production material shortages and distribution limitations, and manage product margins to drive year-over-year growth and market share gains in the third quarter of 2021. However, due to the widespread supply chain and logistics issues, demand outpaced our ability to deliver products, order growth significantly outpaced revenue growth, and our backlog grew substantially during the quarter.
Further, we have increased the employee capacity at the majority of our facilities in compliance with local COVID-19 guidelines and have implemented additional safety and space management protocols to help ensure the health and safety of our employees. We plan to be in compliance with vaccine mandates, including the September 9, 2021 Executive Order on Ensuring Adequate COVID Safety Protocols for Federal Contractors (the “Executive Order”), to the extent applicable to us.
Outlook
Our results in the third quarter of 2021 demonstrated broad-based demand across our portfolio, which we expect to continue in the fourth quarter of 2021. We expect year-over-year revenue from sales of our products and services to increase between 6.5% and 8.5% in the fourth quarter of 2021 and between 14% and 14.5% for the year ending December 31, 2021, based on our current assumptions about easing global virus control measures, continued recovery of certain end markets, elective surgery rates remaining below pre-pandemic levels, the availability of electronic components and our ability to convert backlog, and sustaining workforce levels and manufacturing capacity.
While we expect the positive, broad-based momentum in demand across our portfolio to continue in the fourth quarter of 2021, we will continue deploying and applying the Fortive Business System to help drive near-term performance by actively managing our supply chain and continuing to collaborate with our customers and suppliers to minimize anticipated material and component delays and production and logistics disruptions. We expect these supply chain challenges and inflationary pressures will continue during the fourth quarter of 2021; however, we believe we will largely offset these inflationary cost pressures with price increases and other countermeasures.
36

Table of Contents
Additionally, we are monitoring the risks of new COVID-19 variants which may be more contagious or severe, or less responsive to treatment and vaccines, and may impact the rate that virus control measures ease or become more restrictive, which could impact our future results. Further, we are monitoring the impact of vaccine mandates, including the Executive Order, on our workforce, supply chain, and global manufacturing capacity.
We are also continuing to monitor any escalation of geopolitical uncertainties related to governmental policies toward international trade, monetary and fiscal policies, relations between the U.S. and China, and we are continuing to evaluate the impacts of proposed and recently enacted legislation on our business and the potential impacts of various investment and taxation policy initiatives in the United States and by the Organisation for Economic Co-operation and Development. As of the filing date of this report, we are unable to quantify the anticipated impacts on our financial results for the year ending December 31, 2021, if any, and any impact in future periods, and will continue monitoring these developments.
RESULTS OF OPERATIONS
Sales Growth
The following table summarizes total aggregate year-over-year sales growth and the components of aggregate year-over-year sales growth during the three and nine month periods ended October 1, 2021 as compared to the comparable periods of 2020:
Components of Sales Growth
% Change Three Months Ended
October 1, 2021 vs. Comparable 2020 Period
% Change Nine Months Ended
October 1, 2021 vs. Comparable 2020 Period
Total revenue growth (GAAP) 12.0  % 17.2  %
Existing businesses (Non-GAAP) 9.1  % 12.9  %
Acquisitions (Non-GAAP)
1.7  % 2.0  %
Currency exchange rates (Non-GAAP) 1.2  % 2.3  %
Operating Profit Margins
Operating profit margin was 15.5% for the three month period ended October 1, 2021, an increase of 360 basis points as compared to 11.9% in the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses, price increases, and to a lesser extent, incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives, which were partially offset by higher year-over-year employee compensation costs and higher selling, general, and administrative expenses (“SG&A costs”) due to broad cost reduction efforts in the comparable period of 2020 that reduced expenses to better align with reductions in demand and higher freight and logistics costs — favorable 325 basis points
The year-over-year net effect of acquisition-related transaction costs which were less during the three month period ended October 1, 2021 than those recognized during the comparable period in 2020 — favorable 15 basis points
The year-over-year effect of amortization from existing businesses — favorable 70 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
The year-over-year net effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue — unfavorable 50 basis points
37

Table of Contents
Operating profit margin was 15.7% for the nine month period ended October 1, 2021, an increase of 500 basis points as compared to 10.7% in the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses and price increases, and to a lesser extent, lower year-over-year material costs, incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives, and a favorable sales mix, which were partially offset by higher year-over-year employee compensation costs and higher SG&A costs due to broad cost reduction efforts in the comparable periods of 2020 that reduced expenses to better align with reductions in demand and higher freight and logistics costs — favorable 270 basis points
The year-over-year net effect of acquisition-related transaction costs which were less in the nine month period ended October 1, 2021 than those recognized in the comparable period in 2020 — favorable 110 basis points
The year-over-year effect of amortization from existing businesses — favorable 100 basis points
The year-over-year effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue and inventory which were less in the nine month period ended October 1, 2021 than those recognized in the comparable period in 2020 — favorable 20 basis points
Business Segments
Sales by business segment for each of the periods indicated were as follows ($ in millions):
  Three Months Ended Nine Months Ended
  October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Intelligent Operating Solutions $ 535.4  $ 459.1  $ 1,588.1  $ 1,338.8 
Precision Technologies 455.7  418.5  1,375.0  1,187.1 
Advanced Healthcare Solutions 308.4  282.2  915.3  783.6 
Total $ 1,299.5  $ 1,159.8  $ 3,878.4  $ 3,309.5 
INTELLIGENT OPERATING SOLUTIONS
Our Intelligent Operating Solutions segment provides leading solutions to accelerate industrial and facility reliability and performance, as well as compliance and safety across a range of vertical end markets, including manufacturing, process industries, healthcare, utilities and power, communications and electronics, among others. The businesses in our Intelligent Operating Solutions segment provide a broad and differentiated offering of instrumentation, sensors, software, and services to address these critical workflows for our customers.
38

Table of Contents
Intelligent Operating Solutions Selected Financial Data
  Three Months Ended Nine Months Ended
($ in millions) October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales $ 535.4  $ 459.1  $ 1,588.1  $ 1,338.8 
Operating profit 90.0  77.5  313.4  213.0 
Depreciation 6.1  7.4  18.3  27.2 
Amortization 40.9  37.6  116.8  113.4 
Operating profit as a % of sales 16.8  % 16.9  % 19.7  % 15.9  %
Depreciation as a % of sales 1.1  % 1.6  % 1.2  % 2.0  %
Amortization as a % of sales 7.6  % 8.2  % 7.4  % 8.5  %
Components of Sales Growth
  % Change Three Months Ended
October 1, 2021 vs. Comparable 2020 Period
% Change Nine Months Ended
October 1, 2021 vs. Comparable 2020 Period
Total revenue growth (GAAP) 16.6  % 18.6  %
Existing businesses (Non-GAAP) 13.1  % 14.7  %
Acquisitions (Non-GAAP) 2.2  % 1.3  %
Currency exchange rates (Non-GAAP) 1.3  % 2.6  %
Year-over-year sales of products and services from existing businesses of Intelligent Operating Solutions increased 13.1% and 14.7% during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020. The year-over-year results for both respective periods were driven by broad-based increases in demand, particularly from our industrial channel partners, critical safety, facilities, and maintenance SAAS product offerings, and portable gas detection instruments. The results during the nine month period ended October 1, 2021 were partially offset by a decline in demand for our industrial imaging products, as demand for those products was elevated during the comparable period in 2020 for COVID-19 monitoring.
Geographically, demand from existing businesses in our Intelligent Operating Solutions segment increased in both developed and high growth markets during the three and nine month periods ended October 1, 2021. The results in both respective periods were driven by growth in every major geography, led by North America and Europe, and to a lesser extent, China and Latin America.
Year-over-year price increases in our Intelligent Operating Solutions segment contributed 2.1% and 1.6% to sales growth during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020, and is reflected as a component of the change in sales from existing businesses.
Operating profit margin decreased 10 basis points during the three month period ended October 1, 2021 as compared to the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses, price increases, and to a lesser extent, incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives, which were partially offset by higher SG&A costs due to broad cost reduction efforts in the comparable period of 2020 that reduced expenses to better align with reductions in demand and higher year-over-year material and freight costs — favorable 310 basis points
The year-over-year effect of amortization from existing businesses — favorable 120 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
The year-over-year effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue — unfavorable 200 basis points
The incremental year-over-year dilutive effect of acquisition-related transaction costs — unfavorable 240 basis points
39

Table of Contents
Operating profit margin increased 380 basis points during the nine month period ended October 1, 2021 as compared to the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses, price increases, a favorable sales mix, and to a lesser extent, lower year-over-year material costs and incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives, which were partially offset by higher year-over-year employee compensation and SG&A costs due to broad cost reduction efforts in the comparable period of 2020 that reduced expenses to better align with reductions in demand and increased investment in key growth and innovation initiatives — favorable 370 basis points
The year-over-year effect of amortization from existing businesses — favorable 130 basis points
Year-over-year operating profit margin comparisons were unfavorably impacted by:
The incremental year-over-year net dilutive effect of acquisition-related transaction costs — unfavorable 90 basis points
The year-over-year effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue — unfavorable 30 basis points
PRECISION TECHNOLOGIES
Our Precision Technologies segment supplies technologies to a broad set of vertical end markets, enabling our customers to accelerate the development of innovative products and solutions. We provide our customers with electrical test and measurement instruments and services, energetic material devices, and a broad portfolio of sensor and control system solutions.
Precision Technologies Selected Financial Data
  Three Months Ended Nine Months Ended
($ in millions) October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales $ 455.7  $ 418.5  $ 1,375.0  $ 1,187.1 
Operating profit 101.1  82.1  301.1  232.7 
Depreciation 6.3  6.0  18.9  19.4 
Amortization 4.2  4.2  12.7  13.0 
Operating profit as a % of sales 22.2  % 19.6  % 21.9  % 19.6  %
Depreciation as a % of sales 1.4  % 1.4  % 1.4  % 1.6  %
Amortization as a % of sales 0.9  % 1.0  % 0.9  % 1.1  %
Components of Sales Growth
  % Change Three Months Ended
October 1, 2021 vs. Comparable 2020 Period
% Change Nine Months Ended
October 1, 2021 vs. Comparable 2020 Period
Total revenue growth (GAAP) 8.9  % 15.8  %
Existing businesses (Non-GAAP) 7.7  % 13.7  %
Acquisitions (Non-GAAP)
—  % —  %
Currency exchange rates (Non-GAAP) 1.2  % 2.1  %
Year-over-year sales of products and services from existing businesses of Precision Technologies increased 7.7% and 13.7% during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020. The year-over-year results for both respective periods were driven by broad-based demand for test and measurement instruments, increased demand for sensing technologies in the industrial and semiconductor end markets, and increased demand for energetic materials, which were partially offset by a decrease in demand in the medical end market for ventilator components that supported COVID-19 patient treatment efforts in the comparable periods of 2020.
Geographically, demand from existing businesses in our Precision Technologies segment increased in developed markets and slightly declined in high growth markets during the three month period ended October 1, 2021, driven by growth in North America, Europe, and Asia that was partially offset by slight declines in Latin America and Middle East and Africa. For the
40

Table of Contents
nine month period ended October 1, 2021, demand increased in both developed and high growth markets and the results were driven by growth in every major geography, led by North America, Asia, and Europe.
Year-over-year price increases in our Precision Technologies segment contributed 2.3% and 1.5% to sales growth during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020, and is reflected as a component of the change in sales from existing businesses.
Operating profit margin increased 260 basis points during the three month period ended October 1, 2021 as compared to the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses, price increases, and incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives, which were partially offset by higher year-over-year employee compensation expense, and to a lesser extent, higher material and freight costs — favorable 250 basis points
The year-over-year effect of amortization from existing businesses — favorable 10 basis points
Operating profit margin increased 230 basis points during the nine month period ended October 1, 2021 as compared to the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses, price increases, and incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives, and to a lesser extent, lower year-over-year material costs, which were partially offset by higher year-over-year employee compensation costs and an unfavorable sales mix — favorable 210 basis points
The year-over-year effect of amortization from existing businesses — favorable 20 basis points
ADVANCED HEALTHCARE SOLUTIONS
Our Advanced Healthcare Solutions segment serves healthcare customers with enabling products and services for critical activities that help ensure safe, efficient, and timely healthcare. Through the Advanced Healthcare Solutions segment, we provide broad hardware and software portfolio offerings optimized around our end-users’ most critical workflows, including instrument and device reprocessing, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation safety monitoring, and asset management.
Advanced Healthcare Solutions Financial Data
  Three Months Ended Nine Months Ended
($ in millions) October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales $ 308.4  $ 282.2  $ 915.3  $ 783.6 
Operating profit 34.4  1.8  75.8  (15.9)
Depreciation 4.9  4.2  15.6  12.1 
Amortization 35.3  35.3  105.9  106.3 
Operating profit as a % of sales 11.2  % 0.6  % 8.3  % (2.0) %
Depreciation as a % of sales 1.6  % 1.5  % 1.7  % 1.5  %
Amortization as a % of sales 11.4  % 12.5  % 11.6  % 13.6  %
41

Table of Contents
Components of Sales Growth
  % Change Three Months Ended
October 1, 2021 vs. Comparable 2020 Period
% Change Nine Months Ended
October 1, 2021 vs. Comparable 2020 Period
Total revenue growth (GAAP) 9.3  % 16.8  %
Existing businesses (Non-GAAP) 4.7  % 8.7  %
Acquisitions (Non-GAAP)
3.7  % 6.0  %
Currency exchange rates (Non-GAAP) 0.9  % 2.1  %
Year-over-year sales of products and services from existing businesses of Advanced Healthcare Solutions increased 4.7% and 8.7% during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020. The year-over-year results in the three month period ended October 1, 2021 were driven by increased demand for sterilization capital equipment and consumables, radiation safety monitoring, and surgical instrument tracking SAAS products. The year-over-year results in the nine month period ended October 1, 2021 were driven by increased demand for sterilization capital equipment and consumables, radiation safety monitoring, cell therapy equipment design and manufacturing, and surgical instrument tracking SAAS products.
Several of our Advanced Healthcare Solutions businesses are impacted by elective surgical procedure volumes, which decreased from pre-COVID-19 levels at a rate in the low teens across most major geographic markets during the third quarter of 2021. We expect elective surgical procedure volumes in the fourth quarter of 2021 to remain largely consistent with those realized in the third quarter of 2021 and continue to be below 2019 benchmark rates by a high single-digit rate.
Geographically, demand from existing businesses in our Advanced Healthcare Solutions segment increased in both developed and high growth markets during the three and nine month periods ended October 1, 2021. The results in both respective periods were driven by growth in North America and Asia, and growth in Europe contributed to the results in the nine month period ended October 1, 2021.
Year-over-year price increases in our Advanced Healthcare Solutions segment contributed 2.3% and 1.4% to sales growth during the three and nine month periods ended October 1, 2021, respectively, as compared to the comparable periods of 2020, and is reflected as a component of the change in sales from existing businesses.
Operating profit margin increased 1,060 basis points during the three month period ended October 1, 2021 as compared to the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses, a favorable sales mix, price increases, and to a lesser extent, lower year-over-year material costs, which were partially offset by higher year-over-year employee compensation costs and changes in foreign currency exchange rates — favorable 380 basis points
The year-over-year net effect of acquisition-related transaction costs which were less in the three month period ended October 1, 2021 than those recognized in the comparable period in 2020 — favorable 460 basis points
The year-over-year effect of amortization from existing businesses — favorable 105 basis points
The year-over-year effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue and inventory which were less in the three month period ended October 1, 2021 than those recognized in the comparable period in 2020 — favorable 115 basis points
Operating profit margin increased 1,030 basis points during the nine month period ended October 1, 2021 as compared to the comparable period of 2020. Year-over-year operating profit margin comparisons were favorably impacted by:
Higher year-over-year sales volumes from existing businesses, a favorable sales mix, price increases, and to a lesser extent, lower year-over-year material costs, which were partially offset by higher year-over-year freight and logistics costs and higher year-over-year employee compensation costs — favorable 105 basis points
The year-over-year net effect of acquisition-related transaction costs which were less in the nine month period ended October 1, 2021 than those recognized in the comparable period in 2020 — favorable 610 basis points
The year-over-year effect of amortization from existing businesses — favorable 190 basis points
42

Table of Contents
The year-over-year effect of acquired businesses, including amortization, and acquisition-related fair value adjustments to deferred revenue and inventory which were less in the nine month period ended October 1, 2021 than those recognized in the comparable period in 2020 — favorable 125 basis points
COST OF SALES AND GROSS PROFIT
  Three Months Ended Nine Months Ended
($ in millions) October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales $ 1,299.5  $ 1,159.8  $ 3,878.4  $ 3,309.5 
Cost of sales (555.3) (508.2) (1,666.8) (1,463.1)
Gross profit $ 744.2  $ 651.6  $ 2,211.6  $ 1,846.4 
Gross profit margin 57.3  % 56.2  % 57.0  % 55.8  %
The year-over-year increase in cost of sales during the three month period ended October 1, 2021, as compared to the comparable period in 2020, is due primarily to higher year-over-year sales volumes from existing businesses, and to a lesser extent, incremental expenses from our recently acquired businesses and higher year-over material and freight and logistics costs, which were partially offset by restructuring and productivity and improvement initiatives. The year-over-year increase in cost of sales during the nine month period ended October 1, 2021, as compared to the comparable period in 2020, is due primarily to higher year-over-year sales volumes from existing businesses, which was partially offset by lower year-over material costs and productivity improvement initiatives. Year-over-year changes in currency exchange rates increased cost of sales during the three and nine month periods ended October 1, 2021.
The year-over-year increase in gross profit and gross profit margin for the three and nine month periods ended October 1, 2021, as compared to the comparable periods in 2020, is due primarily to higher year-over-year sales volumes, price increases, and a favorable sales mix, which were partially offset by changes in foreign currency exchange rates and higher freight and logistics costs. Gross profit and gross profit margin for the three month period ended October 1, 2021 were also unfavorably impacted by higher year-over-year material costs.
OPERATING EXPENSES
 
Three Months Ended Nine Months Ended
($ in millions)
October 1, 2021 September 25, 2020 October 1, 2021 September 25, 2020
Sales $ 1,299.5  $ 1,159.8  $ 3,878.4  $ 3,309.5 
Selling, general and administrative (“SG&A”) expenses 455.6  434.8  1,340.1  1,253.4 
Research and development (“R&D”) expenses 87.8  79.2  261.8  237.4 
SG&A as a % of sales 35.1  % 37.5  % 34.6  % 37.9  %
R&D as a % of sales 6.8  % 6.8  % 6.8  % 7.2  %
SG&A expenses increased during the three and nine month periods ended October 1, 2021 as compared to the comparable periods of 2020. The year-over-year increase in SG&A expenses for both respective periods was primarily driven by higher employee compensation costs and SG&A expenses due to broad cost reduction efforts in the comparable periods of 2020 to better align with reductions in demand, and to a lesser extent, changes in foreign currency exchange rates. Lower year-over-year net acquisition-related costs and incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives partially offset the increase in SG&A expenses in both respective periods. Incremental SG&A expenses and amortization from ServiceChannel also impacted the results for the three month period ended October 1, 2021.
On a year-over-year basis, SG&A expenses as a percentage of sales decreased 240 and 330 basis points during the three and nine month periods ended October 1, 2021, respectively, primarily due to demand for our products and services which grew at a faster rate than our fixed costs. Additionally, lower year-over-year net acquisition-related costs and incremental year-over-year cost savings associated with restructuring and productivity improvement initiatives reduced SG&A expenses as a percentage of sales.
R&D expenses (consisting principally of internal and contract engineering personnel costs) increased during the three and nine months ended October 1, 2021 as compared to the comparable periods of 2020 primarily due to targeted investments in key growth initiatives and innovation. On a year-over-year basis, R&D expenses were flat as a percentage of sales during the three month period ended October 1, 2021. During the nine month period ended October 1, 2021, R&D expenses decreased as a percentage of sales, reflecting demand for our products and services that grew at a faster rate than our investments in key growth initiatives and innovation.
43

Table of Contents
INTEREST COSTS
For a discussion of our outstanding indebtedness, refer to Note 6 to the consolidated condensed financial statements.
Net interest expense for the three and nine month periods ended October 1, 2021 was $25 million and $78 million compared to $37 million and $112 million for the three and nine month periods ended September 25, 2020, respectively. The year-over-year decrease in interest expense was due to lower year-over-year average debt balances.
INCOME TAXES
Our effective tax rate for the three and nine month periods ended October 1, 2021 was 13.2% and 11.1% as compared to 13.4% and 17.7%, respectively, for the three and nine month periods ended September 25, 2020. The effective tax rate for the three month period ended October 1, 2021 was relatively consistent with the effective tax rate for the three month period ended September 25, 2020. The year-over-year decrease in the effective tax rate for the nine month period ended October 1, 2021 as compared to the nine month period ended September 25, 2020 was due primarily to a permanent difference on the gain on our Retained Vontier Shares due to the tax-free treatment of our disposition of the shares through the Debt-for-Equity Exchange, a reduction to our uncertain tax positions, and increases in certain federal tax benefits for the nine month period ended October 1, 2021. Additionally, the tax costs incurred during the nine month period ended September 25, 2020 associated with the repatriation of a portion of our previously reinvested earnings outside of the United States contributed to the year-over year decrease in the effective tax rate for the nine month period ended October 1, 2021.
Our effective tax rate for the three and nine month periods ended October 1, 2021 differs from the U.S. federal statutory rate of 21% due primarily to the positive and negative effects of the Tax Cuts and Jobs Act, U.S. federal permanent differences, the impact of credits and deductions provided by law, and a reduction in our uncertain tax positions. Specific to the nine month period ended October 1, 2021, our effective tax rate also differs from the U.S. federal statutory rate of 21% due to a permanent difference on the gain on our Retained Vontier Shares due to the tax-free treatment of our disposition of the shares through the Debt-for-Equity Exchange. Specific to the nine month period ended September 25, 2020, our effective tax rate also differs from the U.S. federal statutory rate of 21% due to the repatriation of a portion of our previously reinvested earnings outside of the United States.
COMPREHENSIVE INCOME
Comprehensive income decreased by $175 million during the three month period ended October 1, 2021 as compared to the comparable period in 2020 due primarily to unfavorable changes in foreign currency translation adjustments of $100 million and net earnings that were lower by $75 million.
Comprehensive income increased by $29 million during the nine month period ended October 1, 2021 as compared to the comparable period in 2020 due primarily to net earnings that were higher by $44 million, partially offset by unfavorable changes in foreign currency translation adjustments of $17 million.
LIQUIDITY AND CAPITAL RESOURCES
We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. We generate substantial cash from operating activities and believe that our operating cash flow and other sources of liquidity, which consist of access to bank loans, commercial paper, capital markets, and our revolving credit facility will be sufficient to allow us to continue funding and investing in our existing businesses, consummate strategic acquisitions, make interest and principal payments on our outstanding indebtedness, fulfill our contractual obligations, and manage our capital structure on a short and long-term basis.
We have generally satisfied any short-term liquidity needs that are not met through operating cash flows and available cash through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”). Due to the volatility and disruption in the commercial paper markets during the first six months of 2020, we temporarily reduced our reliance on this source of funding, and consequently paid down and refinanced our outstanding commercial paper with a 364-day delayed-draw term loan due March 22, 2021 (the “Term Loan due March 2021”) that was subsequently retired in the Debt-for-Equity Exchange. In August 2021, we resumed borrowing under our Commercial Paper Program to fund, in part, the ServiceChannel acquisition.
Credit support for the Commercial Paper Programs is provided by a five-year $2.0 billion senior unsecured revolving credit facility that expires on November 30, 2023 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit
44

Table of Contents
support for the commercial paper programs, can also be used for working capital and other general corporate purposes. As of October 1, 2021, no borrowings were outstanding under the Revolving Credit Facility.
The availability of the Revolving Credit Facility as a standby liquidity facility to repay maturing commercial paper is an important factor in maintaining the existing credit ratings of the Commercial Paper Programs when we have outstanding borrowings. We expect to limit any future borrowings under the Revolving Credit Facility to amounts that would leave sufficient credit available under the facility to allow us to borrow, if needed, and repay any outstanding commercial paper as it matures.
We continue to monitor the financial markets and general global economic conditions and if changes in financial markets or other areas of the economy adversely affect our access to the capital markets, we would expect to rely on a combination of available cash and existing available capacity under our credit facilities to provide short-term funding.
Overview of Cash Flows and Liquidity
Following is an overview of our cash flows and liquidity for the nine month period ended October 1, 2021:
  Nine Months Ended
($ in millions) October 1, 2021 September 25, 2020
Total operating cash provided by continuing operations $ 705.9  $ 648.3 
Cash paid for acquisitions, net of cash received $ (1,156.7) $ (15.2)
Payments for additions to property, plant and equipment (28.0) (58.9)
All other investing activities 1.1  5.3 
Total investing cash used in continuing operations $ (1,183.6) $ (68.8)
Net proceeds from (repayment of) commercial paper borrowings $ 215.0  $ (1,141.9)
Proceeds from borrowings (maturities greater than 90 days), net of issuance costs of $8 million in 2020 —  741.7 
Repayment of borrowings (maturities greater than 90 days) (611.1) (250.0)
Payment of common stock cash dividend to shareholders (72.6) (70.7)
Payment of mandatory convertible preferred stock cash dividend to shareholders (34.5) (34.5)
All other financing activities 18.1  (0.6)
Total financing cash used in continuing operations $ (485.1) $ (756.0)
Operating Activities
Operating cash flows from continuing operations can fluctuate significantly from period-to-period as working capital needs and the timing of payments for income taxes, pension funding, and other items impact reported cash flows.
Operating cash flows from continuing operations were $706 million during the first nine months of 2021, an increase of $58 million, or 9%, as compared to the comparable period of 2020. The year-over-year change in operating cash flows from continuing operations was primarily attributable to the following factors:
Operating cash flows were impacted by higher net earnings for the first nine months of 2021 as compared to the comparable period in 2020. Net earnings for the nine month period ended October 1, 2021 were impacted by a year-over-year increase in operating profit of $254 million, a decrease in net interest expense of $34 million associated with the net repayment of debt, a gain on the Retained Vontier Shares of $57 million and a gain on litigation dismissal of $26 million, which were partially offset by the loss on extinguishment of debt of $105 million. The gain on the Retained Vontier Shares and litigation dismissal, and substantially all of the loss on the extinguishment of debt, are non-cash items that impact net earnings without a corresponding impact to operating cash flows.
The aggregate of accounts receivable, inventories, and trade accounts payable used $52 million of cash during the first nine months of 2021 as compared to providing $64 million in the comparable period of 2020. The amount of cash flow generated from or used by the aggregate of accounts receivable, inventories, and trade accounts payable depends upon how effectively we manage the cash conversion cycle, which generally represents the number of days that elapse from the day we pay for the purchase of raw materials and components to the collection of cash from our customers, and can be significantly impacted by the timing of collections and payments in a period.
45

Table of Contents
The aggregate of prepaid expenses and other assets and accrued expenses and other liabilities used $55 million of cash during the first nine months of 2021 as compared to providing $45 million of cash in the comparable period of 2020. The year over year change was largely driven by the funding of the $36 million deferred compensation liability associated with the ServiceChannel acquisition, which was paid into escrow upon closing of the transaction, and various compensation and benefit payments.
Investing Activities
Investing cash flows from continuing operations consist primarily of cash paid for acquisitions and capital expenditures, and increased $1.1 billion during the nine month period ended October 1, 2021 as compared to the comparable period of 2020. The increase in investing cash flows was due to the $1.2 billion acquisition of ServiceChannel that was partially offset by a year-over-year decrease in capital expenditures of $31 million largely due to higher spending in the comparable period in 2020 related to the integration of the ASP business.
Capital expenditures are made primarily for increasing capacity, replacing equipment, supporting product development initiatives, improving information technology systems, and purchasing equipment that is used in revenue arrangements with customers. For the year ending December 31, 2021, we expect capital spending to be approximately $50 million, although actual expenditures will ultimately depend on business conditions.
Financing Activities and Indebtedness
Financing cash flows from continuing operations consist primarily of cash flows associated with the issuance of equity, the issuance and repayments of debt and commercial paper, and payments of quarterly cash dividends to shareholders.
Financing activities from continuing operations used cash of $485 million during the nine month period ended October 1, 2021, reflecting the following transactions:
On January 21, 2021, we repaid the remaining $317 million outstanding of the Delayed-Draw Term Loan Due 2020 using the cash proceeds received from Vontier in the Vontier Separation.
On February 9, 2021, we repurchased $281 million of the 0.875% Convertible Senior Notes due 2022 using the remaining cash proceeds received from Vontier in the Separation and other cash on hand. In connection with the repurchase, we recorded a loss on debt extinguishment during the nine month period ended October 1, 2021 of $10.5 million.
During the third quarter of 2021, we resumed borrowing under our Commercial Paper Programs to fund, in part, the ServiceChannel acquisition. As of October 1, 2021, commercial paper outstanding under the U.S. dollar-denominated commercial paper program had a weighted annual effective rate of 0.19% and a weighted average remaining maturity of approximately 12 days.
In the comparable 2020 period, financing activities from continuing operations used $756 million of cash, reflecting borrowings from our Term Loan due March 2021, which were more than offset by repayments of commercial paper of $1.1 billion and $250 million of our 2020 Term Loan.
On January 19, 2021, we completed the non-cash Debt-for-Equity Exchange of 33.5 million shares of common stock of Vontier, representing all of the Retained Vontier Shares, for $1.1 billion in aggregate principal amount of indebtedness of the Company held by Goldman Sachs & Co., including (i) all $400.0 million of the Term Loan due March 2021 and (ii) $683.2 million of the Term Loan due May 2021. We recorded a loss on extinguishment of the debt included in the Debt-for-Equity Exchange of $94.4 million in the nine month period ended October 1, 2021.
Refer to Note 6 to the consolidated condensed financial statements for information regarding our financing activities and indebtedness.
Aggregate cash payments for preferred and common stock dividends paid to shareholders during the nine month period ended October 1, 2021 were $107 million and are recorded as dividends to shareholders in the Consolidated Condensed Statement of Changes in Equity and the Consolidated Condensed Statement of Cash Flows.
Cash and Cash Requirements
As of October 1, 2021, we held approximately $838 million of cash and equivalents that were invested in highly liquid investment-grade instruments with a maturity of 90 days or less that yielded insignificant interest income during the three and nine month periods ended October 1, 2021. Approximately 80% of the $838 million of cash and equivalents we held as of October 1, 2021 was held outside of the United States.
46

Table of Contents
We have cash requirements to support working capital needs, capital expenditures and acquisitions, pay interest and service debt, pay taxes and any related interest or penalties, fund our pension plans as required, pay dividends to shareholders, and support other business needs or objectives. With respect to our cash requirements, we generally intend to use available cash and internally generated funds to meet these cash requirements, but in the event that additional liquidity is required, particularly in connection with acquisitions and repayment of maturing debt, we may also borrow under our commercial paper programs or credit facilities or enter into new credit facilities and either borrow directly thereunder or use such credit facilities to backstop additional borrowing capacity under our commercial paper programs. We also may from time to time access the capital markets, including to take advantage of favorable interest rate environments or other market conditions.
Foreign cumulative earnings remain subject to foreign remittance taxes. We have made an election regarding the amount of earnings that we do not intend to repatriate due to local working capital needs, local law restrictions, high foreign remittance costs, previous investments in physical assets and acquisitions, or future growth needs. For most of our foreign operations, we make an assertion regarding the amount of earnings in excess of intended repatriation that are expected to be held for indefinite reinvestment. No provisions for foreign remittance taxes have been made with respect to earnings that are planned to be reinvested indefinitely. The amount of foreign remittance taxes that may be applicable to such earnings is not readily determinable given local law restrictions that may apply to a portion of such earnings, unknown changes in foreign tax law that may occur during the applicable restriction periods caused by applicable local corporate law for cash repatriation, and the various tax planning alternatives we could employ if we repatriated these earnings.
As of October 1, 2021, we expect to have sufficient liquidity to satisfy our cash needs for the foreseeable future.
CRITICAL ACCOUNTING ESTIMATES
There were no material changes during the three and nine month periods ended October 1, 2021 to the items we disclosed as our critical accounting estimates in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 Annual Report on Form 10-K.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our concentrations of credit risk arising from receivables from customers are limited due to the diversity of our customers. Our businesses perform credit evaluations of their customers’ financial conditions as appropriate and also obtain collateral or other security when appropriate.
Additional quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Financial Instruments and Risk Management,” in our 2020 Annual Report on Form 10-K. There were no material changes during the three and nine month periods ended October 1, 2021 to the information reported in our 2020 Annual Report on Form 10-K relating to our evaluation of interest rate, foreign currency exchange, and commodity price risk.
ITEM 4. CONTROLS AND PROCEDURES
Our management, with the participation of the President and Chief Executive Officer, and the Senior Vice President and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the President and Chief Executive Officer, and the Senior Vice President and Chief Financial Officer, have concluded that, as of the end of such period, these disclosure controls and procedures were effective.
There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the most recent completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1A. RISK FACTORS

Information regarding risk factors appears in “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Information Relating to Forward-Looking Statements,” in Part I - Item 2 of this Form 10-Q and in the “Risk Factors” section of our 2020 Annual Report on Form 10-K. There were no material changes during the quarter ended October 1, 2021 to the risk factors reported in the “Risk Factors” section of our 2020 Annual Report on Form 10-K.
47

Table of Contents


ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the fiscal quarter ended October 1, 2021, we acquired the following shares in settlement of the withholding obligations pertaining to vesting of our Performance Stock Awards:
Period
Total number
of shares
(or units)
purchased (1)
Average price
paid per share
(or unit)  (1)
Total number
of shares (or units)
purchased
as part of publicly
announced plans or
programs
Maximum number
(or approximate dollar
value) of shares
(or units) that may yet be
purchased under the
plans or programs
July 3 - July 31 6,352  $ 70.72  N/A N/A
August 1 - August 31 —  —  N/A N/A
September 1 - October 1 —  —  N/A N/A
Total 6,352  $ 70.72  N/A N/A
(1) In connection with the vesting of Restricted Stock Awards (“RSAs”) of the Company granted to James A. Lico on July 5, 2016 and in accordance with the terms of the Company’s 2016 Stock Incentive Plan, the Company withheld 6,352 shares of the Company’s common stock based on the corresponding closing price to offset tax withholding obligations that arose upon vesting of the RSAs.


48

Table of Contents
ITEM 6. EXHIBITS
Exhibit
Number    
   Description
3.1
3.2
3.3
10.1
31.1   
31.2   
32.1   
32.2   
101.INS    XBRL Instance Document (1) - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.
101.SCH    Inline XBRL Taxonomy Extension Schema Document (1)
101.CAL    Inline XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEF    Inline XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LAB    Inline XBRL Taxonomy Extension Label Linkbase Document (1)
101.PRE    Inline XBRL Taxonomy Extension Presentation Linkbase Document (1)
104
The cover page from this Quarterly Report on Form 10-Q for the quarter ended October 1, 2021, formatted in Inline XBRL and contained in Exhibit 101
*Indicates management contract or compensatory plan, contract or arrangement
(1)     Exhibit 101 to this report includes the following documents formatted in Inline XBRL (Extensible Business Reporting Language): (i) Consolidated Condensed Balance Sheets as of October 1, 2021 and December 31, 2020, (ii) Consolidated Condensed Statements of Earnings for the three and nine month periods ended October 1, 2021 and September 25, 2020, (iii) Consolidated Condensed Statements of Comprehensive Income for the three and nine month periods ended October 1, 2021 and September 25, 2020, (iv) Consolidated Condensed Statement of Changes in Equity for the three and nine month periods ended October 1, 2021 and September 25, 2020, (v) Consolidated Condensed Statements of Cash Flows for the nine month periods ended October 1, 2021 and September 25, 2020, and (vi) Notes to Consolidated Condensed Financial Statements.
49

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
FORTIVE CORPORATION:
Date: October 28, 2021 By: /s/ Charles E. McLaughlin
Charles E. McLaughlin
Senior Vice President and Chief Financial Officer
Date: October 28, 2021 By: /s/ Christopher M. Mulhall
Christopher M. Mulhall
Chief Accounting Officer
50